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Abstract  
During the resorbable-polymer-boom of the 1970s and 1980s, polycaprolactone 
(PCL) was used in the biomaterials field and a number of drug-delivery devices. Its 
popularity was soon superseded by faster resorbable polymers which had fewer perceived 
disadvantages associated with long term degradation (up to 3-4 years) and intracellular 
resorption pathways; consequently, PCL was almost forgotten for most of two decades. 
Recently, a resurgence of interest has propelled PCL back into the biomaterials-arena. The 
superior rheological and viscoelastic properties over many of its aliphatic polyester 
counterparts renders PCL easy to manufacture and manipulate into a large range of implants 
and devices. Coupled with relatively inexpensive production routes and FDA approval, this 
provides a promising platform for the production of longer-term degradable implants which 
may be manipulated physically, chemically and biologically to possess tailorable degradation 
kinetics to suit a specific anatomical site. This review will discuss the application of PCL as a 
biomaterial over the last two decades focusing on the advantages which have propagated its 
return into the spotlight with a particular focus on medical devices, drug delivery and tissue 
engineering. 
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1. Introduction 
Polycaprolactone (PCL) was one of the earliest polymers synthesized by the 
Carothers group in the early 1930s [1]. It became commercially available following efforts to 
identify synthetic polymers that could be degraded by microorganisms [2]. PCL can be 
prepared by either ring-opening polymerisation of ε-caprolactone using a variety of anionic, 
cationic and coordination catalysts or via free radical ring-opening polymerisation of 2-
methylene-1-3-dioxepane [3]. PCL is a hydrophobic, semicrystalline polymer; its crystallinity 
tends to decrease with increasing molecular weight. The good solubility of PCL, its low 
melting point (59-64 C) and exceptional blend-compatibility has stimulated extensive 
research into its potential application in the biomedical field [4-6]. Consequently, during the 
resorbable-polymer-boom of the 1970s and 1980s, PCL and its copolymers were used in a 
number of drug-delivery devices. Attention was drawn to these biopolymers owing to their 
numerous advantages over other biopolymers in use at that time. These included tailorable 
degradation kinetics and mechanical properties, their ease of shaping and ease of manufacture 
enabling appropriate pore sizes conducive to tissue in-growth, and the controlled delivery of 
drugs contained within their matrix. Functional groups could also be added to render the 
polymer more hydrophilic, adhesive, or biocompatible which enabled favourable cell-
responses. Due to the fact that PCL degrades at a slower rate than polyglycolide (PGA), 
polyD,L-lactide (PDLA) and its copolymers and was therefore originally used in drug 
delivery devices that remain active for over one year and in slow degrading suture materials 
(Maxon™).  
 
Although initially attracting some research attention, PCL was soon overwhelmed by 
the popularity of other resorbable polymers such as polylactides and polyglycolides, which 
were studied in applications which demanded the polymer matrix to release encapsulated 
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drugs within days or weeks with a complete resorption 2-4 months after implantation. The 
medical device industry was interested in replacing metal devices (plates, screws, nails etc) 
by using biodegradable implants; however PCL did not have the mechanical properties to be 
applied in high load bearing applications. Furthermore, both the medical device and drug 
delivery community felt that faster resorbable polymers also had fewer perceived 
disadvantages associated with the long term degradation (up to 3-4 years for PCL) and 
intracellular resorption pathways; consequently, PCL was almost forgotten for most of two 
decades.  
 
A resurgence of interest has propelled PCL back into the biomaterials/arena with the 
birth of a new field, namely tissue engineering; a trend which is depicted graphically in 
Figure 1. This huge resurgence of interest during the 1990s and 2000s has stemmed from the 
realization that PCL possesses superior rheological and viscoelastic properties over many of 
its resorbable-polymer counterparts which renders it easy to manufacture and manipulate into 
a large range of scaffolds, some of which are shown in Figure 2. In reality, PCL can be used 
in a wide range of scaffold fabrication technologies as described in section 8.1 and its 
relatively inexpensive production routes, compared with other aliphatic polyesters, is hugely 
advantageous. Furthermore, the fact that a number of drug-delivery devices fabricated with 
PCL already have FDA approval and CE Mark registration enables a faster avenue to market. 
Interestingly, in spite of these clear advantages, PCLs are not widely exploited by many 
research groups from a translational point of view. This review will discuss the applications 
of PCL as a biomaterial over the last two decades, including its relationship with other 
bioresorbable polymers. It will focus on the properties and advantages which have 
propagated PCL’s return into the spotlight of drug delivery and especially the tissue 
engineering arena. 
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2. Synthesis and Physicochemical Properties of PCL  
  PCL is prepared by the ring opening polymerisation of the cyclic monomer ε-
caprolactone and was studied as early as the 1930s [1]. Catalysts such as stannous octoate are 
used to catalyze the polymerisation and low molecular weight alcohols can be used to control 
the molecular weight of the polymer [7]. 
 
  There are various mechanisms which affect the polymerisation of PCL and these are 
anionic, cationic, co-ordination and radical. Each method affects the resulting molecular 
weight, molecular weight distribution, end group composition and chemical structure of the 
copolymers [5]. PCL is a semi-crystalline polymer having a glass transition temperature (Tg) 
of −60◦ C and melting point ranging between 59 and 64◦ C, dictated by the crystalline nature 
of PCL which enables easy formability at relatively low temperatures. The number average 
molecular weight of PCL samples may generally vary from 3,000 to 80,000 g/mol and can be 
graded according to the molecular weight [8].  
 
  PCL is soluble in chloroform, dichloromethane, carbon tetrachloride, benzene, 
toluene, cyclohexanone and 2-nitropropane at room temperature. It has a low solubility in 
acetone, 2-butanone, ethyl acetate, dimethylformamide and acetonitrile and is insoluble in 
alcohol, petroleum ether and diethyl ether [9]. PCL can be blended with other polymers to 
improve stress crack resistance, dyeability and adhesion and has used in combination with 
polymers such as cellulose propionate, cellulose acetate butyrate, polylactic acid and 
polylactic acid-co-glycolic acid for manipulating the rate of drug release from microcapsules. 
[4]. 
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 In the 1970’s it had already been recognised that PCL is particularly amenable to 
blending and polymer blends based on PCL were thus categorized with three types of 
compatibility; firstly exhibiting only a single Tg; secondly as mechanically compatible, 
exhibiting the Tg values of each component but with superior mechanical properties and 
thirdly as incompatible, exhibiting the enhanced properties of phase-separated material [10]. 
Compatibility of PCL with other polymers depends on the ratios employed and is generally 
used to have better control over the permeability of the delivery systems. Copolymers (block 
and random) of PCL can be formed using many monomers, e.g. ethyleneoxide, 
polyvinylchloride, chloroprene, polyethylene glycol, polystyrene, diisocyanates(urethanes), 
tetrahydrofuran (THF), diglycolide, dilactide, δ-valerlactone, substituted caprolactones, 4-
vinyl anisole, styrene, methyl methacrylate and vinyl acetate. [5]. 
 
Physico-mechanical properties of several degradable polymers, amongst them PCL, 
have been investigated and compared by Engelberg et al who investigated thermal properties 
(Tg, crystallization, melting and decomposition points) and tensile properties including 
Young's modulus, tensile strength and elongation at yield and break [11]. Some of these 
properties are listed in Table 1. 
 
3. Biodegradation  
When one considers biopolymers it is important to keep in mind that something which 
is biodegradable does not necessarily translate to being bioresorbable, that is, as it degrades 
and moves away from their site of action in vivo it is not necessarily removed from the body. 
In contrast, bioresorbability is a concept which reflects total elimination of the initial foreign 
materials and bulk degradation products by-products (low molecular weight compounds) with 
no residual side effects [12]. The definitions of biodegradable, bioresorbable, bioabsorbable 
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and bioerodable, according to Vert, are detailed in Table 2, appropriate categorization of 
these properties are of fundamental importance in the discussion of polymer-based materials 
particularly in biomedical applications. 
 
PCLs can be biodegraded by outdoor living organisms (bacteria and fungi) but they 
are not biodegradable in animal and human bodies because of the lack of suitable enzymes 
[13]. That is not to say they are not bioresorbable, but rather, the process takes much longer, 
propagating firstly via hydrolytic degradation. It is widely accepted that hydrolytic 
degradation of poly (α-hydroxy) esters can proceed via surface or bulk degradation pathways, 
depicted schematically in Figure 3. What determines the means by which this pathway 
proceeds is the diffusion-reaction phenomenon. Surface degradation or erosion involves the 
hydrolytic cleavage of the polymer backbone only at the surface [14]. This situation arises 
when the rate of hydrolytic chain scission and the production of oligomers and monomers, 
which diffuse into the surroundings, is faster than the rate of water intrusion into the polymer 
bulk. This typically results in thinning of the polymer over time without affecting the 
molecular weight of the internal bulk of the polymer which would generally remain 
unchanged over the degradation period (Figure 3a). The advantage to this type of erosion is 
the predictability of the process, giving desirable release vehicles for drugs as release-rates 
can be predetermined [15]. 
 
Bulk degradation occurs when water penetrates the entire polymer bulk, causing 
hydrolysis throughout the entire polymer matrix (Figure 3b). Random hydrolytic chain 
scission would take place and produce an overall reduction in molecular weight. If water 
molecules can diffuse into the polymer bulk, hydrolyse the chains enabling the monomers or 
oligomers to diffuse out, erosion will occur gradually and equilibrium for this diffusion-
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reaction phenomenon would be achieved. If this equilibrium is disturbed, the degradation 
mechanism could provoke internal auto-catalysis, via the carboxyl and hydroxyl end group 
by-products. Whereas surface oligomers and carboxyl groups may freely diffuse into the 
surroundings (surface erosion situation), in the case of bulk degradation the internal 
concentration of autocatalysis products can produce an acidic gradient as each newly 
generated carboxyl end group formed during ester bond cleavage accumulates. This in turn 
accelerates the internal degradation compared to the surface leaving an outer layer of higher 
molecular weight skin with a lower molecular weight, degraded, interior (Figure 3c). The 
degradation mechanism thus becomes defined by bimodal molecular weight distribution. 
When the inner oligomers become small enough, they diffuse rapidly through the outer layer 
and this is accompanied by an onset of weight loss and a decrease in the rate of chain scission 
producing a higher molecular weight hollowed out structure. The rapid release of these 
oligomers and acid by-products can result in inflammatory reactions in vivo as reported in the 
bioresorbable device literature [16]. Furthermore, if the surrounding tissue is unable to buffer 
the pH change due to poor vascularisation or low metabolic activity then local, temporary 
disturbances may arise – an example of this has been observed from fibre reinforced PGA 
pins used during orthopedic surgery which led to increased osmotic pressure through local 
fluid accumulation at the time of rapid degradation [17]. 
 
The homopolymer PCL has a total degradation of two to four years (depending of the 
starting molecular weight of the device or implant) [18-20]. The rate of hydrolysis can be 
altered by copolymerisation with other lactones or glycolides/lactides [3]. Extensive studies 
by the authors group concerning in vitro and in vivo degradation of PCL scaffolds detected no 
evidence of internal catalysis evidenced by uniform molecular weight distribution over time 
and cross sectional examination of the scaffold struts over a 6 month [21] and 36 month (non-
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published) period. Other degradation studies using PCL in separate in vitro (saline) and in 
vivo (rabbit) conditions reported that both hydrolytic degradation rates were similar and thus 
concluded that enzymatic involvement in the first stage of degradation phase (0-12 month) 
was not a significant factor in the degradation process [22, 23].  
 
From degradation studies presented in the literature it can be concluded that PCL  
undergoes a two-stage degradation process: firstly the non-enzymatic hydrolytic cleavage of 
ester groups and secondly, when the polymer is more highly crystalline and of low molecular 
weight (less than 3000) the polymer is shown to undergo intracellular degradation as 
evidenced by observation of PCL fragments uptake in phagosomes of macrophages and giant 
cells and within fibroblasts [24] which supports the theory that PCL may be completely 
resorbed and degraded via an intracellular mechanism once the molecular weight was 
reduced to 3000 or less. It was also noted that in the first stage the degradation rate of PCL is 
essentially identical to the in vitro hydrolysis at 40°C and obeyed first-order kinetics. It was 
concluded that the mechanism of PCL degradation could be attributed to random hydrolytic 
chain scission of the ester linkages, which caused a decrease in molecular weight.  
 
Ali et al studied the mechanism of PCL degradation in vitro by mean of gel 
permeation chromatography (GPC), differential scanning calorimetry (DSC) and scanning 
electron microscopy (SEM). It was hypothesized that the HO·radical was likely to be a 
significant cause of PCL degradation in implantable devices [25]. Chen et al studied the in 
vitro degradation behavior of the PCL microparticles and compared these with that of PCL 
film in PBS at 37±1°C at pH7.4. The shape of PCL was found to have no obvious effect on 
its degradation rate, which suggested that homogeneous degradation dominated the process.  
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Recently, accelerated degradation models for PCL have been investigated primarily 
by thermal methods by several groups [26]. Persenaire et al. proposed a two-stage thermal 
degradation mechanism of PCL [27] and found in the first stage there was a statistical rupture 
of the polyester chains via ester pyrolysis reaction. The second stage led to the formation of 
ε-caprolactone (cyclic monomer) as result of an unzipping depolymerisation process. 
Sivalingam et al. investigated the thermal degradation in bulk and solution [28, 29] and found 
that the polymer degraded by random chain scission and specific chain end scission in 
solution and bulk, respectively. 
 
Pitt et al showed that the mechanism of in vivo degradation of PCL, PLA and their 
random copolymers was qualitatively the same. The degradation rate of random copolymers 
was much higher than those of the homopolymers under the same conditions [30]. On the 
other hand, the degradation rate of PCL/PLA block copolymers was found to be intermediate 
of PCL or PLA homopolymers and increased with PLA content in the 0-40% range [31]. 
However when the PLA content was greater than 40%, the degradation was found to exceed 
that of the homopolymers [32]. Degradation kinetics are highly dependent upon the 
molecular weight of the polymer(s). High molecular weight structures take much longer to 
degrade, as mediated through the chain length of the polymer. Higher molecular weight 
increases the chain length necessitating a greater number of ester bonds to be cleaved in order 
to generate water soluble monomers/oligomers to allow erosion to proceed; degradation 
consequently takes longer. Woodward and coworkers studied the in vivo (Dawley rats) and 
intracellular degradation of PCL and reported that degradation first proceeded with non-
enzymatic bulk hydrolysis, and a transient initial inflammatory response occurred only for the 
first 2 weeks [24]. After 9 months, only when the molecular weight had reduced to 
approximately 5000 g/mol, did a loss in mass emerge and subsequently the PCL implants 
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fragmented. Figure 4 schematically depicts the interplay between the mass loss and molecular 
weight loss from a typical resorbable polymer scaffold in vivo. 
 
For the study of intracellular degradation, low molecular weight PCL (Mn, 3000 
g/mol) powders, 53-500 nm, were used. The authors reported that the powdered PCL was 
rapidly degraded and absorbed within 13 days inside the phagosomes of macrophage and 
giant cells, and that the sole metabolite was 6-hydroxyl caproic acid. Figure 5a illustrates the 
mechanism by which PCL degrades hydrolytically. Hydrolysis intermediates 6-hydroxyl 
caproic acid and acetyl coenzyme A are formed which in turn enter the citric acid cycle and 
are eliminated from the body [33]. 
 
More recently Sun et al designed a long-term study in which in vivo degradation of 
PCL was observed for 3 years in rats [23]. Distribution, absorption and excretion of PCL 
were traced in rats using radioactive labeling. The results showed that PCL capsules with 
initial Mw of 66 000 g/mol remained intact in shape during 2-year implantation, and broke 
into low Mw (8000 g/mol) pieces at the end of 30 months. The Mw of PCL deceased linearly 
with time. Tritium-labeled PCL (Mw 3000 g/mol) was subcutaneous implanted in rats to 
investigate its absorption and excretion and the radioactive tracer was first detected in plasma 
15 days post-implantation. At the same time, radioactive excreta were recovered from feces 
and urine. An accumulative 92% of the implanted radioactive tracer was excreted from feces 
and urine at 135 days post-implantation. In parallel, the plasma radioactivity dropped to 
background level. Radioactivity in the organs was also close to background level confirming 
that the material did not accumulate in body tissue and could be completely excreted which 
was in accordance with early studies by Pitt et al [34]. 
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Pulkkinen et al demonstrated that 2,2-bis(2-oxazoline) linked PCL (PCL-O) was 
degraded in vitro enzymatically by surface erosion which could enable the novel use of this 
material for drug delivery and other biomedical applications. The degradation, erosion 
(weight loss) and toxicity of PCL-O poly(ester-amide)s were evaluated in vivo. PCL and 
three PCL-O polymers with different PCL block lengths (Mn: 1500, 3900, 7500 g/mol) were 
melt-pressed in the form of discs and implanted subcutaneously in Wistar rats (dose 
approximately 340 mg/kg) for 1, 4 and 12 weeks. With an implantation of 12 weeks, up to 
16.5% weight loss of polymer discs was measured for the most extensively linked PCL-O 
polymer (block length 1500 g/mol) whereas practically no weight loss was observed with the 
other polymers. Nuclear magnetic resonance (NMR), DSC and GPC studies as well as SEM 
micrographs before and after implantation and in vitro hydrolysis studies collectively 
indicated that enzyme based surface erosion of PCL-O polymers occurred in vivo. The in vivo 
evaluation based on results from hematology, clinical chemistry and histology of the 
implantation area and main organs (i.e. heart, lung, liver, kidney, spleen and brain) 
demonstrated that PCL-O polymers were biocompatible and safe, enzyme-sensitive 
biomaterials [35]. 
 
Surprisingly, despite more than 1000 papers being published during the last decade in 
the biomaterials and tissue engineering literature (Figure 1) which use PCL-based-scaffolds, 
only a small number of groups have included a study of the degradation and resorption 
kinetics of the PCL scaffolds. 
 
The authors group have undertaken several long-term degradation studies of ordinary 
(Sigma) and medical grade (Birmingham Polymers) PCL scaffolds both in vitro and in vivo 
[21]. An accelerated degradation systems  based on NaOH was also developed and validated 
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against a system based on simulated physiological conditions [36]. Figure 5b illustrates 
surface erosion of PCL and the associated changes in crystallinity over time (owing to its 
crystalline and amorphous components) which can lead to cyclic increasing and decreasing 
crystallinities throughout the degradation period. Microscopic and macroscopic views of an 
accelerated degradation system are shown in Figure 5c. PCL scaffolds were degraded from 0 
to 5 weeks and were observed to degrade via a surface erosion pathway homogenously 
throughout the scaffold structure, through the thinning of the filament diameters.  
 
As previously described, PCL is an excellent candidate for co-polymerisation or 
blending to engineer desired mechanical properties and degradation kinetics of a medical 
device or scaffold. A Dutch group were amongst the first to use PCL based copolymers to 
design and commercialize nerve guides device. The degradation and the tissue response 
evoked by poly(1,3-trimethylene carbonate) [poly(TMC)] and copolymers of TMC with 
either 52 mol % D,L-lactide (DLLA) or 89 mol % ε-caprolactone (CL) were evaluated in 
vivo by subcutaneous implantation of polymer films in rats for periods up to one year [37]. 
Poly(TMC) specimens were extensively degraded after 3 weeks and, as confirmed by 
histology, totally resorbed in less than a year. A fast linear decrease in thickness and mass 
without a change in molecular weight was observed. Initially an acute sterile inflammatory 
tissue reaction, caused by the implantation procedure, was observed, followed by a mild 
macrophage-mediated foreign body reaction that lasted during the resorption period of the 
polymer. It was concluded that in vivo, poly(TMC) degraded via surface erosion involving 
cellular-mediated processes. The degradation of the copolymers was slower than that of 
poly(TMC), taking place via autocatalyzed bulk hydrolysis, preferentially of ester bonds. The 
TMC-DLLA copolymer degraded 20 times faster than the TMC-CL one. In both cases, the 
tissue reaction upon implantation resembled a so called sterile inflammatory reaction 
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followed by a foreign body reaction that was defined by a fibrous encapsulation. Significant 
mass loss was only observed for the TMC-DLLA copolymer, which underwent 96% mass 
loss in 1 year. When extensive mass loss started, a mild-to-moderate secondary foreign body 
reaction, related to clearance of the polymer fragments, was triggered. The results presented 
in this study demonstrate that poly(TMC) and both TMC copolymers (TMC-DLLA and 
TMC-CL) are biodegradable and biocompatible materials, making these polymers attractive 
for the preparation of short and long-term degradable devices for soft tissue engineering [37].  
 
In conclusion, the degradation of PCL compared to PLA, PGA, copolymers thereof 
and many other resorbable polymers is slow, making it much more suitable for long-term 
degradation applications such as delivery of encapsulated molecules extending over a period 
of more than one year, which will be discussed in section 5. 
 
4. Biocompatibility  
Originally biocompatibility referred to the ability of a material to perform with an 
appropriate host response in a specific application [38]. However, more recent definitions are 
aiming to describe the biological mechanism in more detail (Williams 2007 Trends in 
biotechnology). In vitro biocompatibility or cytotoxicity is generally evaluated through cell 
culture systems. In vivo experimental, histological and pathological examination of the peri-
implant and host responses - such as immunogenic, carcinogenic and thrombogenic responses 
are also studied. The complexity of these host responses is a result of a series of temporal and 
spatial processes involving numerous closely interdependent mechanisms of material-tissue 
interactions. It is these interactions that control the ultimate performance of a material within 
a biological environment. If we consider the field of biostable materials and permanently 
implanted devices/implants, the primary goal is minimizing and adjusting material-tissue 
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interactions. The interaction of the living environment and the material should be acceptable 
and stable for long-term therapies and performances. Conversely, in the field of 
biodegradable and bioresorbable polymers, the situation is quite the opposite with an added 
dimension of complexity afforded by the degradation and resorption by-products of the 
implants, which are able to strongly interact with living systems. From this point of view, 
biodegradable and bioresorbable polymers must be regarded as much closer to pharmacology 
than to material science. Hence, biocompatibility is a factor that must be considered before 
the selection of biodegradable polymers to be used in medical devices, scaffolds and drug 
delivery systems. 
 
In general, bioresorbable polymers and devices are well tolerated by living tissue [39], 
with their biocompatibilities depending primarily on the factors briefly discussed below. The 
leaching of low molecular mass compounds either through degradation or because of the 
presence of leachable impurities is the mayor cause of triggering inflammation. Release of 
acidic degradation products from bioresorbable polymers and implants is also a large 
contributor to the observed secondary inflammatory reactions. Another important factor 
which influences inflammation responses is the site of implantation. If the capacity of the 
surrounding tissues to eliminate the by-products is low, due to poor vascularization or low 
metabolic activity, the chemical composition of the by-products may lead to local temporary 
disturbances. One example of this is the increase of osmotic pressure or change in pH 
manifested by local fluid accumulation or transient sinus formation [17]. Hence, problems of 
biocompatibility of bioresorbable polymers such as aliphatic polyesters are unquestionably 
related to biodegradability and bioresorbability.  
 
The determination of both the degradation rate of the polymer and the local tissue 
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clearance is crucial in predicting the concentration of by-products present in the tissue and 
resultant host response. Originally, the inflammatory response of copolymers PCL and PLA 
after implantation in male wistar rats was studied in detail by by Pitt et al [24]. The injection 
of microspheres into the body resulted in the activation of neutrophils and causes mild 
localized inflammation. The rapid activation of neutrophils by PCL microspheres was 
confirmed by measurement of superoxide anion generation as measured by 
chemiluminescence. Neutrophils activation released chemotactic factors leading to influx of 
massive number of neutrophils into the affected site and causing inflammation. Phagocytosis 
of drug loaded polymeric microspheres by white blood cells was shown to be the main 
clearance mechanism by which foreign material was eliminated from the body [24]. 
Inflammatory reactions in bones were less pronounced than in muscles. Even so the 
investigators do not discuss this observation in great detail one might hypothesize that the 
pronounced primary inflammatory reaction in muscle might be due to a better vascularization 
of muscle tissue and a greater amount of implanted material.  
 
The tissue reaction of implantable microspheres comprising PCL prepared by solvent 
evaporation methods was studied by implantation in the brain of wistar rats [40]. Results 
indicated no necrosis was observed which implied good biocompatibility of microspheres 
within the brain tissue. To prevent the phagocytosis of microspheres, modification of 
microspheres surface can be undertaken by steric stabilization. Flow cytometry has been used 
to study the effect of PCL microspheres on apoptosis and cell cycle of fibroblasts. Results 
revealed that PCL microspheres purified in different ways showed different 
cytocompatibility; with well-purified microspheres having supeior cytocompatibility [41]. 
 
Both PCL and PLLA are slow degrading polymers but their biocompatibility resulting 
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from degradation is quite different. Bergsma et al reported foreign body reactions to PLLA 
bone plates and screws [16]. Six out of ten patients had to be reoperated after postoperative 
periods between 35 and 44 months due to swelling at the implantation site. The authors 
reported no discoloration of the overlaying tissue, with no signs of acute or subcutaneous 
inflammation, or an increase in temperature or pain on palpation. Light microscopic analysis 
of the soft tissue showed a foreign body reaction without signs of inflammation around the 
PLLA. On the outer part of the PLLA a few polymorphonuclear leucocytes were present 
whereas the inner part was surrounded by dense connective tissue lying within macrophages, 
foreign body giant cells, and fibrocytes. The authors hypothesized that the observed foreign 
body reaction was a combination of a biochemical and biomechanical reaction of the crystal-
like PLLA fragments [16].  
 
Pistner et al (1993) and Gutwald et al (1994) studied two amorphous and one 
crystalline PLA in the paravertebral muscle of rats. The crystalline PLA remained almost 
stable in form and structure over a period of 116 weeks. No signs of inflammation and a mild 
foreign body reaction were observed. After 116 weeks, the amorphous PLA of higher 
molecular weight almost completely resorbed, whereas the amorphous PLA of lower 
molecular weight was metabolized. During the degradation and resorption period a mild to 
moderate histiocytic inflammation was found [42-44]. 
 
 As discussed above it is crucially important to study biocompatibility not only from a 
short-term point of view but also in the long-term. Unfortunately most in vivo studies in the 
tissue engineering field suffer from being prematurely ended in order to extract histological 
and/or biomechanical data before the PCL scaffold itself has been cleared from the 
implantation site. It’s accepted that long term in vivo data is costly to acquire but this does not 
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negate the need to have robust information pertaining to long term degradation of the 
microspheres and scaffold, the biocompatibility, the mechanical properties of the 
scaffold/new tissue and the ultimate outcome of implantation after months or even years.  
 
Meek et al (2009) recognised a scarcity in literature on long-term nerve guide studies 
of Neurolac(R), after having shown that small fragments of the nerve guide comprising 
poly(DL-lactide-ε-caprolactone) [PDLLA-PCL] (which were assumed to fully resorb) could 
still be found on the edge of the epineurium of the regenerated nerve after implantation. 
Consequently they studied the 2-year degradation and possible long-term foreign body 
reaction against the nerve guides after implantation in the sciatic nerve of the rat. They 
demonstrated that nerve regeneration took place through the scaffold, and after 2-years of 
implantation no remains of the implant could be found macroscopically. However, 
microscopically, the polymer fragments along with multinucleated giant cells and 
macrophages were found along the regenerated nerve tissue. Hence, the authors concluded 
that a 3-year study was warranted to capture the nerve tissue after complete clearance of the 
polymer by the system [45]. 
 
 Several studies by Hutmacher et al have looked at both the short term and long term 
biocompatibility of PCL scaffolds using different animal models and some this work is 
summarized in Figure 6 [21, 46-49]. Figure 6a shows the surgical implantation of the 5mm 
diameter PCL scaffolds into the parietal bone of the rabbit/rabbit. Figure 6b shows the 
explanted rabbit skull. Upper insets depict micro computed-topography (µCT) images of the 
mineralised bone within the critical sized skull defects/scaffold sites after 2-years 
implantation (empty defects showed incomplete bridging of the defects). Furthermore the 
histology (lower insets) demonstrated some new bone formation in the centre of the PCL 
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scaffolds/defect sites, as detected using von kossa staining which binds to calcium salts and 
turns black. Further development of these scaffolds by the authors has led to the production 
of second-generation scaffolds which are composite by nature and contained PCL with 
20wt% tricalcium phosphate (TCP). Figure 6c depicts histology from a rat calvarial critical-
sized models used to study the effect of PCL-TCP composite scaffolds implanted for 15 
weeks, with some scaffold groups containing 5 µg rhBMP2 (recombinant human bone 
morphogenetic proteins, the primary interest in this growth factor family arises from their 
effective use in clinical bone regeneration). By 15 weeks, PCL–TCP/rhBMP2 defects 
exhibited complete healing of the calvarium as shown by histological staining in Figure 6c. 
The scaffold alone also stimulated some bone formation at this relatively early stage, 
compared with no healing observed for empty defects. These studies compound the 
biocompatibility of the PCL and PCL composites with no adverse biocompatibility effects 
found at short-term time points of 15 week up to long-term implantations of 2 years. 
 
 
5. PCL Applied in Drug Delivery Systems. 
PCL is suitable for controlled drug delivery due to a high permeability to many drugs 
excellent biocompatibility and its ability to be fully excreted from the body once bioresorbed. 
Biodegradation of PCL is slow in comparison to other polymers, so it is most suitable for 
long-term delivery extending over a period of more than one year. PCL also has the ability to 
form compatible blends with other polymers which can affect the degradation kinetics which 
in turn can be tailored to fulfill desired release profiles [50-52]. 
 
 The delivery of therapeutic compounds can be hindered by their poor water solubility, 
however, recent advances in drug formulation have obviated the potential of colloidal vectors 
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to act as efficient solubilising agents in such cases [53]. The capacity of block copolymer 
micelles to increase the solubility of hydrophobic molecules stems from their structural 
composition, which is characterized by a hydrophobic core sterically stabilized by a 
hydrophilic corona. The former serves as a reservoir in which the drug molecules can be 
incorporated by means of chemical, physical or electrostatic interactions, depending on their 
physicochemical properties [53]. Drug release rates from PCL depends on type of 
formulation, method of preparation, PCL content, size and percent of drug loaded in the 
microcapsules. Due to a higher permeability of PCL it is blended with other polymers to 
improve stress, crack resistance, dyeability and control over release rate of drugs. Within the 
last decades, PCL polymers have been major area of interest to develop controlled delivery 
systems especially for peptides and proteins [52]. 
 
 Lemmouchi et al have investigated the in vitro and in vivo release of the selected 
drugs, isometamidium chloride and ethidium bromide from PCL-PLLA, PCL-DLLA and 
PCL-TMC rods [54]. 
 
5.1. PCL Microspheres  
 Much research has been focused on degradable polymer microspheres for drug 
delivery. Administration of medication via such systems is advantageous because 
microspheres can be ingested or injected; they can be tailored for desired release profiles and 
in some cases can even provide organ-targeted release [51]. 
 
A microencapsulated drug is a promising drug delivery system with obvious 
advantages, such as improving the therapeutic efficiency and efficacy, prolonging the 
biological activity, controlling the drug release rate and decreasing the administration 
 
 
20
frequency. As drug microparticles, besides biocompatibility, one of the most important 
requirements is that the matrix material should be biodegraded within a suitable period which 
is compatible with the drug release rate. Hence, biodegradable polymers have been the major 
focus of attempts to develop improved delivery systems for pharmaceutical research. There 
has been extensive research into drug delivery using biodegradable polymeric devices ever 
since bioresorbable surgical sutures entered the market two decades ago. Amongst the 
different classes of biodegradable polymers, the thermoplastic aliphatic poly(esters) such as 
PLA, PGA and especially their copolymers such as poly(lactide-co-glycolide) (PLGA) have 
generated tremendous interest because of their excellent biocompatibility, biodegradability, 
and mechanical strength, most of which can be tailored via the copolymerisation of different 
amounts of each respective polymer. They are easy to formulate into various devices for 
carrying a variety of drug classes such as vaccines, peptides, proteins, and micromolecules. 
Most importantly, they have been approved by the FDA for drug delivery [10]. 
 
 The matrix material of bioresorbable microparticles can be decomposed into non-toxic 
and low molecular weight species concomitant with release of the drug which are then 
metabolized or absorbed by the organism. It is no surprise that a huge research interest is now 
focused on the application of biodegradable microparticles for controlled drugs release. 
Amongst them, polycaprolactone is one of the more widely utilised. The advantages of PCL 
include its high permeability to small drug molecules, and their negligible tendency to 
generate an acidic environment during degradation as compared to PLA and PGAs. The 
degradation of PCL homopolymer is very slow as compared to other polyesters making it 
more suitable for long term delivery systems extending to a period of more than one year, and 
with appropriate blending the delivery can be increased/decreased as desired [10]. 
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 PCL microspheres can be prepared by several different methods, some of which are 
reviewed by Freiberg et al [51]. Colloidal monomers dispersed in a liquid with opposite 
solubilities can be polymerised [55]. Spherical droplets are formed by oil-soluble organic 
monomers dispersed in aqueous media (oil in water, O/W) or by water-soluble monomers 
dissolved in water dispersed in an organic medium (water in oil, W/O) [56]. The 
polymerisation of dispersed monomers is achievable by various methods including emulsion, 
suspension, and dispersion techniques [57]. Emulsions are typically used to form uniform 
spheres on nanometer scales (10–100nm). The resulting polymer beads can be so uniform on 
the nano-scale that they may diffract visible light [58]. Dispersion polymerisation results in 
microspheres of the range 0.5-10µm. The reagents (including monomer, initiator, and 
stabilizer) are dissolved in an organic medium and since the initiator is soluble inside the 
monomer, polymerisation takes place inside the monomer droplets. The polymer beads, 
insoluble in the organic solvent, precipitate, and the stabilizer prevents bead flocculation [59]. 
Significant work on dispersion polymerisation in supercritical CO2 has been undertaken in 
recent years which may be beneficial to medical applications since no toxic solvents are 
involved [60] [61]. 
 
Suspension polymerisation typically gives microspheres in the range of 50-500 µm. In 
suspension polymerisation the monomer is dispersed in a water phase with a stabilizer; the 
initiator is soluble in the monomer phase where polymerisation occurs. The size and quantity 
of the particles is determined by the size and quantity of dispersed monomer droplets and by 
the speed of mechanical stirring [57]. 
 
 Solvent evaporation (also known as the double emulsion technique) and spray drying 
techniques are common techniques for producing microspheres from linear polymers and 
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have been reviewed by Vasir et al (2003)[62]. Briefly, microspheres can be produced by the 
evaporation of an organic solvent from dispersed oil droplets containing both polymer and 
biomolecule [63]. Often a double emulsion is employed whereby the biomolecule is first 
dissolved in water; this aqueous phase is dispersed in an organic solvent (usually 
dichloromethane, DCM), which contains the degradable polymer and the first W/O emulsion 
is formed. Dispersion of the first emulsion in a stabilized aqueous medium (usually using 
poly vinyl alcohol as stabilizer) forms the final O/W emulsion; microspheres are formed as 
the DCM evaporates and the polymer hardens, trapping the encapsulated drug [64]. A major 
obstacle in the entrapment of drugs into microspheres is attaining a high yield via good 
entrapment efficiencies. Many groups fail to achieve a high enough entrapment to warrant 
further production of the microspheres at the risk of losing too much drug in the process 
which is very costly. It is also surprising how few details are provided in many studies which 
detail the method of quantifying drug entrapment efficiencies.  
 
5.2. PCL nanospheres  
 Nanospheres are colloidal drug delivery systems, which act as transport carrier 
compartments for drugs or other active molecules, with size ranging between 10-1000nm. 
Drug particles may be encapsulated, dispersed or absorbed in the nanospheres. They may also 
be termed as nanoparticles or nanocapsules depending upon whether the drug is in a 
polymeric matrix or encapsulated in the shell. Nanospheres and nanocapsules can be prepared 
by the same methods as those described for microparticles, except that manufacturing 
parameters are adjusted to obtain nanometer size droplets. This can be obtained by using a 
relatively small ratio of the dispersed phase to the dispersion medium and a substantially 
higher stirring speed [65]. 
 Nanospheres can be used for selective targeting via the reticuloendothelial system to 
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the liver and to cells that are phagocytically active. The size of nanospheres allows them to be 
administered intravenously via injection unlike many other colloidal systems which occlude 
both needles and capillaries. Injectable nanoparticulate carriers have good applicability for 
specific drug delivery and medical imaging. But they cannot generally be used due to their 
elimination within seconds after intravenous injection by the reticuloendothelial system. To 
overcome this limitation, monodisperse biodegradable nanospheres have been developed 
from amphiphilic copolymers. These nanospheres were shown to exhibit increased blood 
circulation time and reduced drug accumulation in the liver of mice [65].The efficacy of these 
colloidal particles as drug carriers is closely related to their interaction with proteins and 
enzymes in different body fluids. The interaction phenomenon between lysozyme, a 
positively charged enzyme that is highly concentrated in mucosa and two different drug 
carriers: nanocapsules made of an oily core coated by PCL and nanoparticles made solely of 
PCL were analyzed. Results showed that the interaction of lysozyme with these colloidal 
drug carriers was highly affected by their surface charge [66]. Gref et al analysed plasma 
protein adsorption zeta potential and the particle uptake by polymorphonuclear cells by 
biodegradable PEG-coated PLA, PLGA and PCL nanoparticles. The influence of the PEG 
corona thickness and density, as well as the influence of the nature of the core was studied 
[67]. The conditions to stabilize PLGA and the PCL nanoparticles by freeze drying with 
several cryoprotective agents were identified. Studies indicated the necessity of adding 
sucrose, glucose, trehalose or gelatin to preserve the properties of nanoparticles regardless of 
the freezing procedure [68]. 
 
6. Techniques of nanosphere preparation  
 Different methods have been reported in literature for the preparation of drug entrapped 
nanoparticles including, emulsion polymerisation method in continuous aqueous phase, 
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emulsion polymerisation method in continuous organic phase, interfacial polymerisation, 
interfacial disposition, solvent evaporation, desolvation of macromolecules and dialysis 
methods [69]. Select methods for preparing PCL nanospheres are discussed below: 
 
6.1.1.1. Interfacial polymer disposition method  
 Interfacial polymer disposition is a procedure for preparing biodegradable nanospheres 
following displacement of a semi-polar solvent, miscible with water from a lipophilic 
solution. In this method, the polymer is first dissolved in an organic solvent, usually acetone. 
Similarly the mixture of phospholipid is prepared in acetone by increasing the temperature to 
near boiling point, the drug is then dissolved in benzyl benzoate and is added to the acetonic 
solution. The resulting organic solution is poured under stirring into water containing the 
surfactant poloxamer, with the aqueous phase immediately turning into a milky solution; 
indicating the formation of nanocapsules. Acetone is then removed under reduced pressure. 
The colloidal suspension thus formed is concentrated to the desired volume by removal of 
water [70]. Spray-dried polymeric nanocapsules and nanospheres have also been prepared 
from PCL suspensions containing diclofenac using interfacial deposition of the polymer [71]. 
 
6.1.1.2. Dialysis method  
 Indomethacin loaded nanospheres of PCL have been prepared by dialysis methods. The 
polymer was dissolved in organic solvent (dimethylformamide) and the drug was added to 
the solution under constant stirring at room temperature. After removing the organic solvent 
dialysis was undertaken for 24h using cellulose membrane bag. The miceller solution was 
collected from the bag, sonicated and centrifuged to remove aggregated particles and 
unloaded drug. Lyophilization was then performed to obtain nanospheres [72]. 
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6.1.1.3. Emulsion polymerisation method  
 The earliest nanoparticles prepared by the polymerisation of a monomer were those 
proposed by Birrenbach and Speiser in the 1970s [73]. In emulsion polymerisation, droplets 
of water insoluble monomers are emulsified in an external aqueous and acidic phase 
containing a stabilizer. The monomers polymerise relatively fast by an anionic 
polymerisation mechanism, the polymerisation rate being dependent on the pH of the 
medium. At neutral pH, the monomer polymerises extremely fast, leading to the formation of 
aggregates. However, at acidic pH, between pH 2 and 4, the reaction is slowed, yielding 
nanospheres (frequently 200 nm) with a narrow-size distribution. The system is maintained 
under magnetic agitation while the polymerisation reaction takes place. Finally the colloidal 
suspension is neutralized and lyophilized following the incorporation of glucose as a 
cryoprotectant [52]. 
 
 Water soluble drugs may be associated with nanospheres either by dissolving the drug 
in the aqueous polymerisation medium or by incubating blank nanospheres in an aqueous 
solution of the drug. High speed mixing or sonication is a critical step in emulsification of a 
drug or monomer solution into the external phase as it determines the size distribution, of the 
nanoparticles. In order to achieve narrow particle size distribution ultrasonication or high 
speed homogenization is required; hence these parameters should be carefully monitored 
during processing.  
 
 PCL nanospheres encapsulating numerous drugs have been investigated by various 
researchers and have been comprehensively reviewed by Sinha et al [52] who detail the use 
of PCL as a favorable ocular penetration carrier in nanosphere form compared with 
microspheres when used to deliver indomethacin [74]. Calvo et al further concluded that the 
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colloidal nature of PCL nanosphere and nanocapsule carriers was the main factor responsible 
for favorable corneal transport and that cornea penetration was not increased by variation of 
the inner structure or composition of the carriers [66, 75]. This finding was also observed by 
Marchal-Heussler et al in their use of PCL as a colloidal nanoparticle suspension containing 
cartelol, finding the inner oily core of the carrier provided better cartelol entrapment and 
provided a more pronounced effect on intraocular pressure compared with cartelol eye drops 
[76].  
 
 Other drug encapsulations for ophthalmic applications using PCL 
nanospheres/capsules include fluribrofen [77, 78], aceclofenac [79], cyclosporine A [75, 80] 
and Metipranol [81, 82]. Several orally admininstrated PCL nanosphere/nanocapsules have 
been investigated to deliver antihypertensive agents such as isradipine [83]. Many groups 
have utilised PCL copolymers in cancer-related nanoparticle delivery systems. A ligand-
mediated nanoparticulate drug carrier was designed by Kim et al, which could identify a 
specific receptor on the surfaces of tumor cells. Biodegradable poly(ethylene oxide)/PCL 
(PEG/PCL) amphiphilic block copolymers coupled to biotin ligands were synthesized 
harboring the anticancer drug paclitaxel, prepared via micelle formation in aqueous solution. 
Results showed that the biotin-conjugated nanoparticles could improve the selective delivery 
of paclitaxel into cancer cells via interactions with over-expressed biotin receptors on the 
surfaces of cancer cells [84]. Tamoxifen-loaded PEO-PCL nanoparticles were also prepared 
using solvent a displacement process by Shenoy et al. The use of pluronic surfactants (F-68 
and F-108) increased the stabilisation of the particles and achieved preferential tumor 
targeting and a circulating drug reservoir [85]. 
 
7. PCL Applied in Medical devices 
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7.1. Sutures 
 In the past four decades, several studies have been published relating to the 
biocompatibility of sutures made from aliphatic polyesters [86]. The material composition of 
the commercially available sutures are PGA (Dexon™), PLLGA 10/90 (Vicryl®), poly 
(glycolid-co-trimethylencarbonat) 67.5/32.5 (Maxon®), and polydioxanone (PDS). In the 
case of suture materials, inflammatory response is more pronounced for Dexon™ and 
Vicryl® (mononuclear cells, polymorphonuclear leucocytes and lymphocytes, histiocytes and 
multinucleated giant cells) than for Maxon® and PDS (mononuclear macrophages, a few 
neutrophils, multinucleated giant cells, organized collagenous capsule). 
 
A block copolymer of PCL with glycolide, offering reduced stiffness compared with 
pure polyglycolide, is being sold as a monofilament suture by Ethicon, Inc. (Somerville, NJ), 
under the trade name Monacryl® [19]. 
 
7.2. Wound Dressings 
A major pioneer in the characterization and application of resorbable polymers, 
amongst them PCL, was Pitt during the early 1980’s [3]. Pitt and co-workers undertook 
several studies including degradation studies both in vitro [87, 88] and in vivo [30]. Later 
studies involved sub dermal delivery of L-methadone from PCL microspheres [89]. Since 
then, PCL has been utilised as an ultra thin film for dressing cutaneous wounds [90] and has 
also been used as a release vehicle for the chemical antiseptic chlorohexidine [91]. Blending 
PCL with the polymeric antimicrobial complex, poly (vinylpyrrolidone)-iodine to provide a 
ureteral biomaterial with reduced encrustation was investigated by Jones et al. Interestingly, 
they demonstrated a relationship between the degradation rate of the polymer and the 
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resistance to encrustation (the degradation was tailored via altering the high to low molecular 
weight ratio of PCL in the polymer blends) [92]. 
 
7.3. Contraceptive devices 
Almost 10 million women have used the subdermal contraceptive implants including 
Norplant® Jadelle® and Implanon® which have often-traumatic retrieval operations 
associated with their end point. Consequently, the last two decades have seen substantial 
research into developing a biodegradable matrix implant for controlled release of 
contraceptives to circumvent the need for device-retrieval surgery. PCL is a highly desirable 
candidate for this role owing to its slow degradation, biocompatability and FDA approval. 
Dhanaraju et al have prepared and characterised PCL microspheres as an injectable implant 
system for the controlled delivery of contraceptive steroids [93-95].  
 
Sun et al have developed a 2-year contraceptive device comprising PCL/Pluronic F68 
compounds filled with levonorgestral powder which was approved by the SFDA to conduct 
phase II human clinical trials in China [23]. Preclinical studies using rats and dogs 
demonstrated good release kinetics of levonorgestral from this device, with no adverse 
effects. After implant retrieval at 2 years the implant was physically stable with an associated 
drop in the molecular weight of the polymer from 66,000 to 15,000 Da [96]. Recently, multi 
component biomaterials comprising a hydrogel matrix (2-hydroxyethyl methacrylate cross-
linked by ethylene glycol dimethacrylate) with levonorgestral-containing PCL microspheres 
dispersed within were developed by Zalfen et al. Such assemblies show promise owing to the 
combination of several release mechanisms which can tailor the release of encapsulated 
drugs, potential applications include the design of implantable devices with long-term 
activity, as required by contraceptive and hormone replacement treatments [97].  
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7.4. Fixation Devices 
Kulkarni et al [98, 99] and Cutright et al [100] were amongst the first to report 
preliminary experiments on the use of aliphatic polyesters in the design of internal fixation 
devices. Kulkarni et al (1971) used extruded pins of L- and D-PLA for the reduction of 
mandibular fractures in dogs and confirmed minimal inflammatory responses for both 
polymers [98]. Cutright et al (1971) reported data on mandibular fracture reduction in 
monkeys using transosseous ligatures with PLA suture materials [101]. Animals were 
sacrificed from 2 to 12 weeks. At 12 weeks, early features of bony union appeared and the 
sutures became infiltrated by cellular connective tissue with fibroblasts, endothelial cells, 
mononuclear phagocytes and giant cells. Sutures were progressively replaced by bands of 
new collagen and vascular connective tissue. The tissue reaction was limited to the immediate 
perisutural area.  
 
 Studies using pure PCL in orthopaedic applications are rare in the current literature. 
One study involved the fixation of rabbit humeri osteotomies with PCL reinforced with glass 
fibres versus stainless steel, the outcome demonstrating that although the PCL caused less 
stress shielding than stainless steel, the mechanical strength of the PCL was not sufficient for 
load bearing applications owing to high mal-union rates [102]. It should be noted however 
that several studies exist which exploit the positive properties of PCL and blend these with 
other materials producing superior copolymers and composites which may have the desirable 
properties for use in mechanically challenging applications where a more resilient material is 
needed [103]. 
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Rudd et al have studied PCL for application as a resorbable composite implant during 
the last decade, with an aim at craniofacial repair. The PCL was polymerised in situ and has 
been reinforced with several different fibres including knitted vicryl mesh [104], phosphate 
glass fibres [105] and sodium- and calcium-phosphate glass fibres [106]. The studies have 
also included several cell biocompatibility studies [107, 108]. 
 
7.5. Dentistry 
 
  The filling material used in root canal systems during the common dental procedure; 
root canal treatment, has popularly involved gutta-percha in one of its many forms for almost 
100 years. An optimal root filling material should provide a predictable seal, inhibit or kill 
residual bacteria, prevent re-contamination and facilitate periapical healing. The creation of a 
"seal" can be complicated and the final result is often deemed suspect. Alani et al aimed to 
develop a novel PCL/phosphate glass composite deliverable as a root filling and capable of 
releasing ionic species to enable a predictable seal in an aqueous environment. Different 
compositions of PCL-iron phosphate glass composites were produced and delivered into an 
ex vivo root canal model. Standardized root canals were prepared in extracted human teeth. 
The teeth were examined for root filling adaptation and precipitate formation (SEM), ion 
release (Na+, Ca2+, PO43-, P2O74-, P3O93-, and P5O105-), and sealing ability. The experiments 
were controlled with teeth obturated with contemporary gutta-percha and a conventional 
zinc-oxide/eugenol sealer. The adaptation of the PCL composite was statistically significantly 
better than the control groups. Precipitate formation was noted in some specimens but all 
released various ionic species in an inverse proportion to the iron oxide concentration. The 
experimental material exhibited significantly less leakage after 7 days immersion in saline 
compared with those not immersed, or the control GP group. PCL-phosphate glass 
composites showed good potential as a root filling material capable of producing a seal in an 
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aqueous environment without a sealer [109]. 
 
 PCL is also used as the thermoplastic synthetic polymer-based root canal filling 
material recently introduced to the market as part of the composite Resilon™, which also 
contains bioactive glass, bismuth oxychloride and barium sulphate. This material replaces 
gutta-percha cones and is available in the Resilon®/Epiphany System. According to the 
manufacturer, the PCL polymer in Resilon™ provides the material with thermoplastic 
properties that enable its application in techniques that rely on thermoplasticity. According to 
Miner et al [110], the melting point of Resilon™ is the same as that of gutta-percha (60°C). 
 
 Traditionally, the augmentation of bony defects is carried out using allografts, 
xenografts, autogenous bone, and synthetic biomaterials with the transplantation of 
autogenous bone being regarded as the gold standard. Hutmacher [111] and Zein [112] have 
presented a suitable three dimensional PCL scaffold that can be used for mandible 
augmentation purposes. In a clinical study in dogs, Rai et al have regenerated critical-sized 
defects of the mandible with PCL and 20% TCP scaffolds in combination with platelet rich 
plasma [113]. Schuckert et al (2009) reported the first successful clinical case of the 
reconstruction of the anterior mandible on an osteoporotic patient using the 3D PCL scaffold 
in combination with platelet rich plasma, and rhBMP2 in a 71-year-old human female patient. 
A bacterial infection had caused a peri-implantitis in two dental implants leading to a large 
destruction in the anterior mandible. Both implants were removed under antibiotic 
prophylaxis and a PCL scaffold which had been specifically prepared for this clinical case 
containing platelet rich plasma and rhBMP2 (1.2 mg) was inserted. After complication-free 
wound healing, the radiological control demonstrated de novo-grown bone in the anterior 
mandible 6 months postoperatively. Dental implants were inserted in a third operation. A 
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bone biopsy of the newly grown bone, as well as of the bordering local bone, was taken and 
histologically examined. The bone samples were identical and presented vital laminar bone 
demonstrating the success of the procedure [114]. 
 
 
8. PCL Applied in Tissue Engineering  
Tissue engineering can be defined as: "an interdisciplinary field that applies the 
principles of engineering and life sciences toward the development of biological substitutes 
that restore, maintain, or improve tissue function or a whole organ"[115]. Tissue engineering 
was once categorized as a subfield of “Biomaterials”, but having grown in scope and 
importance it can now be considered as a field in its own right. It is the use of a combination 
of cells, engineering and materials methods, and suitable biochemical and physio-chemical 
factors to improve or replace biological functions. Tissue engineering is closely associated 
with applications that repair or replace portions of or whole tissues (i.e., bone, cartilage, 
blood vessels, bladder, etc.). Often, the tissues involved require certain mechanical and 
structural properties for proper functioning. The term has also been applied to efforts to 
perform specific biochemical functions using cells within an artificially-created support 
system (e.g. an artificial pancreas, or a bioartificial liver).  
 
Powerful developments in the multidisciplinary field of tissue engineering have 
yielded a novel set of tissue replacement parts and implementation strategies. Scientific 
advances in biomaterials, stem cells, growth and differentiation factors, and biomimetic 
environments have created unique opportunities to fabricate tissues in the laboratory from 
combinations of engineered extracellular matrices ("scaffolds"), cells, and biologically active 
molecules. A schematic showing this type of approach is depicted in Figure 7 which shows 
the combination of cells and biomolecules with a scaffold. The scaffold must be capable of 
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supporting cell attachment, proliferation and differentiation in vitro and may then be 
transplanted in vivo. Amongst the major challenges now facing tissue engineering is the need 
for more complex functionality, as well as both functional and biomechanical stability in 
laboratory-grown tissues destined for transplantation. The continued success of tissue 
engineering, and the eventual development of true human replacement parts, will grow from 
the convergence of engineering and basic research advances in tissue, matrix, growth factor, 
stem cell, and developmental biology, as well as materials science and bio informatics.  
 
There are a vast array of manufacturing techniques to create scaffolds for tissue 
engineering, but one must pay special attention to the scaffold specifications and understand 
the interplay of factors affecting the material composition and design criteria. The desirable 
feature of any implantable polymeric scaffold material would be synchronization of polymer 
degradation with the replacement by natural tissue produced from cells. Figure 8 gives a 
graphical illustration of this complex interplay showing the molecular weight loss of a 
resorbable scaffold and how this relates to its mass loss and also to the growth of tissue in 
vitro prior to implantation. The degradation and resorption kinetics of the scaffold are 
designed to allow the seeded cells to proliferate and secret their own extracellular matrix in 
the static and dynamic cell-seeding phase (weeks 1-12) as concomitantly the scaffold 
gradually resorbs leaving sufficient space for cell proliferation and new tissue growth. The 
physical support by the 3D scaffold is maintained until the engineered tissue has sufficient 
mechanical integrity to support itself. 
 
As scaffold candidates, the following characteristics are desirable: (i) three 
dimensional and highly porous structures with an interconnected pore network for cell growth 
and flow transport of nutrients and metabolic waste; (ii) biocompatible and bioresorbable 
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with a  controllable degradation and resorption rate to match cell/tissue growth in vitro and/or 
in vivo; (iii) suitable surface chemistry for cell attachment, proliferation and differentiation 
and (iv) mechanical properties to match those of the tissues at the site of implantation [111]. 
In addition, the demanding requirements dictated by orthopaedic scenarios require a certain 
degree of initial mechanical support and as such, polymeric devices alone are insufficient and 
must be combined with additional components such as cells, growth factors and appropriate 
environments [49]. The degradation properties of a scaffold are therefore of crucial 
importance for biomaterial selection and design but also the long-term success of a tissue-
engineered construct.  
 
Scaffolds for tissue engineering have become a large focus of research attention and 
can be fabricated in a wide variety of ways and a biomaterial which lends itself very well to 
scaffold fabrication is PCL. PCL is an incredibly versatile bioresorbable polymer and by way 
of its superior rheological properties it can be used by almost any polymer processing 
technologies to produce an enormous array of scaffolds. The major scaffold fabrication 
technologies in which PCL has been used extensively are summarized in Figure 9 [116] and 
will be discussed in detail in the next section  
 
8.1. Scaffold Fabrication for Tissue Engineering 
A number of fabrication technologies have been applied to process PCL into 3D 
polymeric scaffolds of high porosity and surface area. From a scaffold design and function 
view point each processing methodology has its relative pro and cons. This section aims to 
provide the reader with an overview of the fabrication methods and is by no means an 
exhaustive list but rather aims to comprehensively discuss techniques which are most 
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pertinent to the fabrication of PCL scaffolds. The key rationale, characteristics, and process 
parameters of the currently used scaffold fabrication techniques are presented hereafter. 
 
8.1.1. Conventional techniques 
8.1.1.1. Porogen Leaching 
Porogen-leaching consists of dispersing a template (particles etc.) within a polymeric 
or monomeric solution, gelling or fixing the structure, and removal of the template to result in 
a porous scaffold (Figure 7a). The specific methods to achieve such scaffolds are numerous, 
and porogen-leaching is an inexpensive technique to manufacture cell-invasive scaffolds. 
Scaffold manufacturing methods based on porogen-leaching are capable of producing 
structures with locally porous internal architectures from a diverse array of materials. Local 
pores are voids characteristically defined by small struts and plates or spherical and tubular 
cavities generally less than 300 m in diameter. Highly interconnected voids are desired for 
tissue engineered constructs where local pores are interconnected within local regions of the 
scaffold microstructure. 
Porogen leaching can also yield cavities with defined shape and solvent diffusion 
from emulsions can yield oriented pore structures. Although these methods yield 
interconnected pores that may comprise a continuous conduit throughout a scaffold, the pore 
connectivity is not an intentional result of a prior global design. Rather, the connectivity is a 
random product of variable, local void interconnections that are affected by polymer 
processing parameters. Such random connections may not provide optimal scaffold 
permeability in vitro for cell distribution and in vivo for vascular tissue in-growth [111]. 
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8.1.1.2. Scaffolds produced using phase separation methods 
Phase separation has been employed for decades to produce hollow fibre membranes 
and other polymer membrane structures. Thermally induced phase separation (TIPS) in 
particular has produced a range of scaffolds for tissue engineering (Figure 9b). The 
morphological nature of the scaffold is variable and due to the self-assembling nature of the 
construct, may be combined with porogen leaching to generate macro-architecture within the 
scaffold. Phase separated scaffolds can additionally be moulded into a range of shapes and 
sizes, demonstrating applicability for many tissue engineered constructs. The TIPS technique 
for producing scaffolds is based upon the reduction of polymer solubility when the 
temperature is lowered, or when the polymer is frozen out of solution. These two types of 
TIPS are termed liquid-liquid and solid-liquid phase separation respectively. 
 
Liquid-Liquid Phase Separation 
Scaffold manufacture relies on the controlled phase separation of polymer solutions 
into high and low concentration regions upon cooling. The high concentration regions 
solidify (via crystallization or gelation), while the low polymer concentrations result in the 
pores, ultimately providing the space for penetrating cells. Binary phase diagrams are used to 
determine the polymer/solvent relationship for TIPS, by showing the phase boundaries as a 
function of temperature and composition. Such diagrams provide information on the type of 
liquid-liquid demixing when cooling below an upper critical solution temperature, and result 
in three distinct morphologies. When solutions with low polymer concentrations are cooled, 
the nucleation and growth of polymer rich phases predominates, while cooling high polymer 
concentrations results in gelation followed by nucleation and growth of polymer-poor 
regions. The nucleation and growth of polymer poor phases results in a non cell-invasive 
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material, while the nucleation and growth of polymer-rich phases results in a material without 
the structural integrity (or pore interconnectivity) required for cell invasive scaffolds.  
 
Bicontinuous phases are of greatest importance for tissue engineered constructs, as 
both mechanical integrity and suitable interconnecting porosity for cell-invasion are possible. 
The liquid-liquid demixing mechanism that results in such bicontinuous phases is termed 
spinodal decomposition. Additional quenching routes passing through the meta-stable 
nucleation regions may still result in spinodal decomposition if cooling is rapid enough, since 
time is required to form nucleation-derived structures. Once the phase separated system is 
stabilized, then the solvent is typically removed by vacuum sublimation and a scaffold is 
attained. The combinations of liquid-liquid phase separation and quenching rates, crystallinity 
and vitrification of the polymer phase, and crystallization of the solvent can all influence the 
final morphology. 
 
Solid-Liquid Phase Separation 
If freezing can result prior to liquid-liquid demixing, then the polymer may be 
expelled to the boundaries of the solvent crystallites. A polymer solution separates into two 
phases, a polymer-rich phase and a polymer-lean phase. After the solvent is removed, the 
polymer-rich phase solidifies. Uniaxial freezing is an inexpensive process for manufacturing 
scaffolds with oriented pores, which are desired in applications where guided regeneration is 
desired, such as scaffolds for spinal cord injury and transplantation sheets for retina. The 
scaffold morphology obtained reflects the solvent crystal structure, and therefore crystal 
growth is important. The freezing rate therefore greatly affects the resulting morphology of 
the scaffold.  
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Polymerisation-Induced Phase Separation 
Certain monomeric solutions, when polymerised in excess solvent, liquid-liquid phase 
separate due to an increasing insolubility of the growing polymeric radical. Unlike TIPS, 
such systems do not rely on temperature changes to induce phase separation but require the 
propagating polymeric radical to extract the remaining monomer out of the original solvent. 
When the two liquid phases are separated into a bicontinuous system, the propagating 
radicals in the polymer rich phase result in gelation. 
 
Polymerisation-induced phase separation scaffolds, after formation, are immersed in 
excess water to exchange non-aqueous solvents or to remove any remaining monomer or 
initiator. Solvent removal by freezing, then sublimation, is not required. Such systems also 
have phase-separation boundaries with their formulations, where the morphological nature of 
the scaffold can be macroporous and cell-invasive, or result from solvent nucleation and 
growth mechanisms depending on the polymerisation conditions. 
 
8.1.1.3. Supercritical Fluid Methods 
Gas-foaming of biodegradable polymers found its original application in the 
biomedical sciences in drug delivery applications during the 1980s. It is a scaffold fabrication 
technique that permits solvent free formation of porous materials through generation of gas 
bubbles within a polymer. The use of supercritical fluid technology (typically CO2) enables 
moulded polymers to be pressurized with a gas, until the polymer is saturated. The release of 
pressure results in nucleation and growth of the air bubbles within the material. These 
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bubbles reach up to 100 m; however interconnectivity is required for cell-invasive structures 
and is not always attained in high levels.  
 
Supercritical CO2 has the potential to be an excellent environment within which 
controlled release polymers and dry composites may be formed. The low temperature and dry 
conditions within the fluid offer obvious advantages in the processing of water, solvent or 
heat labile molecules. The low viscosity and high diffusivity of supercritical CO2 offer the 
possibility of novel processing routes for polymer drug composites, but there are still 
technical challenges to overcome, which have been reviewed by Howdle et al for the 
preparation of scaffolds in which the drug is dispersed throughout the polymer phase [117]. 
This technology has resultantly been used increasingly over the last 3 decades for the 
production of valuable biomaterial compounds [118, 119] and to include biomolecules such 
as proteins or DNA and may also be combined with particulate leaching to attain improved 
interconnectivity between pores. 
8.1.2. Textile Technologies 
Cell-invasive fibre-based scaffolds can be produced using methodologies developed 
for the textile industry, but with structures specifically designed for tissue engineering 
applications. Tissue engineering textiles have a relatively high surface area and their ‘value-
added’ application, from an industry with established techniques, is an advantage. 
Additionally, textiles are typically formed into thin meshes and therefore the permeability is 
high, allowing the necessary nutrients to reach the seeded cells. More recently, 
electrospinning has attracted high interest to design and fabricate scaffolds with nanometre 
and submicron diameter fibres. PCL is used in a majority of these studies, and as such, it will 
be described in detail in the next section. 
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8.1.2.1. Classical non-woven textiles 
Traditional fabrication of non-woven textiles is based on the production of continuous 
micron diameter; fibres by extruding a polymer melt or polymer solution through a spinneret 
which is then mechanically drawn onto a winder, or a series of winders, and collected onto a 
spool. The fibre of the diameter is determined by the extrusion rate and the speed(s) of the 
winder(s) with a constant drawing rate paramount for attaining uniform diameter, continuous 
fibres. The extrusion also will affect the crystallinity of the polymer, and therefore influence 
the mechanical strength and degradation behavior. Polymer solutions are also drawn onto 
winders, however, the fibre must pass through a coagulation bath containing a non-solvent 
for the polymer to precipitate. The collected fibres are then chopped into segments, processed 
and compressed into the final scaffolding shapes.  
 
Langer & Vacanti (1993) used this type of scaffold made from PGA for their initial 
bone and cartilage tissue engineering work [115]. Numerous groups around the world since 
followed this route using such non-woven textiles in their experimental set ups. Even with 
significant research-efforts, only  Wagner, Schmelzeisen and coworkers have been successful 
to-date in using non-woven PLGA to tissue engineer bone chips which have seen application 
bone grafts in low-load bearing areas [120, 121].  
 
Oriented bundles of extruded fibres are of particular interest for neural tissue 
engineering. In this instance, the fibres are cut into segments and not air-blown into random 
orientations. It is well known that the shape of the fibre has a strong effect on the guidance of 
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regenerating axons. On flat surfaces, in the absence of chemical or surface bound gradients, 
neurites will grow in random directions. However, when fibres reach diameters below 
approximately 250 nm, the guidance of axons is favoured along the length of the fibre [122]. 
Due to this effect, oriented non-woven bundles of fibres might be promising scaffolds for 
neural tissue engineering. Van Lieshout et al produced multifilament double-bed knitted, 
fibrin- covered PCL scaffolds to potentially function as aortic valves. On testing, it 
demonstrated good durability, proper opening and it showed coaptation upon closing, but had 
higher associated leakage than those of tested porcine valves [123]. This valve is shown in 
Figure 2(g-i). 
 
8.1.2.2. Electrospinning nanofibres 
Electrospinning is a relatively inexpensive manufacturing technique for sub-micron 
and micron diameter fibres from polymer solutions or melts (Figure 9 c,d). Although it is a 
process known since the 1930s, it is a technique still in its relative developmental infancy in 
the commodity industry and recently is enjoying a massive surge of interest in the field of 
tissue engineering. Electrospinning is of great interest as a scaffold fabrication technique, 
since the resulting fibre diameters are in the size range (submicron to nanometer) of the 
extracellular matrix (ECM) microstructures, particularly the higher-ordered collagen 
microfibrils [124]. The flexibility of the electrospun fibres, due to the very high aspect ratio 
(length/diameter), is also beneficial, allowing seeded cells to remodel their surrounds. The 
size of scale is important in this instance; instead of many cells adhering to one fibre as is 
common with microfibres, one cell may adhere to multiple electrospun nanofibres. A plethora 
of research papers have focused on different natural and synthetic polymers but by far PCL is 
the most commonly used polymer in the electrospinning literature. Specific applications of 
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PCL scaffolds made by electrospinning in various tissue engineering applications will be 
discussed in section 8.2 - 8.8. 
 
8.1.3. Solid Free-Form Fabrication 
Solid free-form fabrication (SFF) and rapid prototyping (RP) [49] have been applied 
to fabricate complex shaped tissue engineered constructs. Unlike conventional machining 
which involves constant removal of materials, SFF is able to build scaffolds by selectively 
adding materials, layer-by-layer, as specified by a computer program (Figure 9f-j)). Each 
layer represents the shape of the cross-section of the computer-aided design (CAD) model at 
a specific level. Today, SFF is viewed as a highly potential fabrication technology for the 
generation of scaffold technology platforms. In addition, one of the potential benefits offered 
by SFF technology is the ability to create parts with highly reproducible architecture and 
compositional variation across the entire matrix due to its computer-controlled fabrication 
process. 
 
8.1.3.1. Systems Based on Laser and UV Light Sources 
Stereolithography  
 The stereolithography apparatus (SLA) (Figure 9g) is often considered the pioneer of 
the RP industry with the first commercial system introduced in 1988 by 3D Systems Inc. 
Stereolithography is based on the use of a focused ultra-violet (UV) laser which is vector 
scanned over the top of a liquid bath of a photopolymerizable material. The UV laser causes 
the bath to polymerise where the laser beam strikes the surface of the bath, resulting in the 
creation of a first solid plastic layer at and just below the surface. The solid layer is then 
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lowered into the bath and the laser generated polymerisation process is repeated for the 
generation of the next layer and so on, until a plurality of superimposed layers forming the 
desired scaffold architecture is obtained. The most recently created layer in each case is 
always lowered to a position for the creation of the next layer slightly below the surface of 
the liquid bath. Once the scaffold is complete, the platform rises out of the vat and the excess 
resin is drained. The scaffold is then removed from the platform, washed of excess resin, and 
then placed in a UV oven for a final curing [125]. 
 
For industrial applications the photopolymer resins are mixtures of simple low-
molecular-weight monomers capable of chain-reacting to form solid long-chain polymers 
when activated by radiant energy within specific wavelength range. The commercial 
materials used by SLA equipment are epoxy-based or acrylate-based resins that offer strong, 
durable, and accurate parts/models. However, this material cannot be used as scaffold 
materials due to lack of biocompatibility and biodegradability. Hence, limited selection of 
photopolymerisable biomaterials is a major constraint for the use of the SLA technique in the 
design and fabrication of scaffolds for tissue engineering applications. However, 
biocompatible acrylic, anhydride and polyethylene oxide-based polymers may be explored in 
future research, as they are already in research or clinical stage typically as curable 
bioadhesives or injectable materials. The variation of the laser intensity or traversal speed 
may be used to vary the cross-link or polymer density within a layer so that the properties of 
the material can be varied from position to position within the scaffold. This would allow 
fabrication of so called biphasic or triphasic matrix systems. Microstereolithography in 
particular is thought to offer a great potential for the production of 3D polymeric structures 
with micrometer resolution.  
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Selective Laser Sintering 
Selective laser sintering (SLS) (Figure 9h) also uses a focused laser beam, but to 
sinter areas of a loosely compacted powder. In this method, a thin layer of powder is spread 
evenly onto a flat surface with a roller mechanism. The powder is then raster-scanned with a 
high-power laser beam. The powder material that is struck by the laser beam is fused, while 
the other areas of powder remain dissociated. Successive layers of powder are deposited and 
raster-scanned, one on top of another, until an entire part is complete. Each layer is sintered 
deeply enough to bond it to the preceding layer. However, SLS poses significant material 
constraints for scaffold fabrication and is currently mainly used to make calcium phosphate 
based scaffolds for bone engineering. SLS has the disadvantage that incorporation of 
sensitive biomolecules is difficult because of the need to locally heat the powder layer so as 
to sinter it [111]. 
 
A novel 3D scaffold with branching and joining flow-channel network comprising 
multiple tetrahedral units has been developed as an implantable liver tissue replacement as 
shown in Figure 2j-o. PCL and 80% (w/w) NaCl salt particles serving as porogen were 
applied in a selective laser sintering process to obtain a scaffold with high (89%) porosity, a 
pore size of 100-200 µm and 3D flow channels. Cell biocompatibility studies showed 
promising results using Hep G2 cells and further optimisation of the scaffold is planned with 
different channel dimension and combination with human hepatocyte progenitors [126]. 
 
Solid Ground Curing (SGC)  
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Besides the classical laser-based SLA process, alternative processes using digital 
mask generators (e.g. liquid crystal displays or Digital Mirror Devices, DMD) have been used 
successfully to build structures out of polymers and ceramics. In the rapid prototyping 
literature, this process is also termed Solid Ground Curing (SGC). In contrast to traditional 
UV-laser based SLA machines, DMD systems are significantly cheaper and therefore more 
versatile in respect to material modifications. At the same time, DMD machines can expose a 
whole layer at once, whereas laser-based systems have to scan the contour of the object 
sequentially. DMD systems are based on a digital micro- mirror device. By projecting a 
bitmap onto the photosensitive resin, the liquid resin can be solidified selectively. 
Theoretically, DMD systems can be used to fabricate scaffolds with high resolution and 
geometric complexity. However, a prerequisite is the availability of a light curable 
biocompatible and bioresorbable polymer material. 
 
Khetani and co-workers describe the development of a photopatterning technique that 
allows localized photoencapsulation of live mammalian cells to control the tissue architecture 
[127]. Cell viability was characterized using HepG2 cells, a human hepatoma cell line. The 
utility of this method was demonstrated by photopatterning hydrogels containing live cells in 
various single layer structures, patterns of multiple cellular domains in a single “hybrid” 
hydrogel layer and patterns of multiple cell types in multiple layers. The authors observed 
that UV exposure itself did not cause cell death over the doses and time scale studied, while 
the photoinitiator 2,2-dimethoxy-2-phenyl-acetophenone was itself cytotoxic in a dose-
dependent manner. Furthermore, the combination of UV and photoinitiator was the least 
biocompatible condition presumably due to formation of toxic free radicals.  
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8.1.3.2. Three-dimensional Printing) 
Three dimensional printing (3DP) technology (Figure 9f) was developed at the 
Massachusetts Institute of Technology [128]. 3DP is used to create a solid object by ink-jet 
printing a binder into selected areas of sequentially deposited layers of powder. Each layer is 
created by spreading a thin layer of powder over the surface of a powder bed. The powder 
bed is supported by a piston which descends upon powder spreading and printing of each 
layer (or, conversely, the ink jets and spreader are raised after printing of each layer and the 
bed remains stationary). Instructions for each layer are derived directly from a CAD 
representation of the component. The area to be printed is obtained by computing the area of 
intersection between the desired plane and the CAD representation of the object. The 
individual sliced segments or layers are joined to form the three dimensional structure. The 
unbound powder supports temporarily unconnected portions of the component as the scaffold 
is built but is removed after completion of printing.  
 
The solvent drying rate is an important variable in the production of scaffolds by 
3DP. Very rapid drying of the solvent tends to cause warping of the printed component. 
Much, if not all, of the warping can be eliminated by choosing a solvent with a low vapour 
pressure. Thus, PCL parts prepared by printing chloroform have nearly undetectable amounts 
of warpage, while large parts made with DCM exhibit significant warpage. It has been found 
that it is often an advantage to combine solvents to achieve minimal warping and adequate 
bonding between the biomaterials particles. Thus, an aggressive solvent can be mixed in 
small proportions with a solvent with lower vapour pressure. After the binder has dried in the 
powder bed, the finished component can be retrieved and unbound powder removed for post 
processing, if necessary. 
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The 3DP process is capable of overcoming the limitations of some SFF techniques in 
manufacturing certain designs, such as overhanging structures. The solution lies in the 
layering of powders. As the layers are spread, there is always a supporting platform of 
powder for printing and binding to take place. Thus, as long as the parts are connected 
together, overhanging structures are of no difficulty. However, one drawback of the powder 
supported and powder-filled structure is that the open pores must be able to allow the internal 
unbound powders to be removed, if the part is designed to be porous such as a scaffold for 
tissue engineering applications. The surface roughness and the aggregation of the powdered 
materials also affect the efficiency of removal of trapped materials. The resolution of the 
printer is limited by the specification of the nozzle size and position control of the position 
controller that defines the print head movement. Another factor is the particle size of the 
powder used, which simultaneously determines the layer thickness. A layer thickness 
between 100-400μm can be achieved depending on the printer. The versatility of using a 
powdered material is both an advantage and a constraint of the 3DP process. Most of the 
available biomaterials do not come in the powder form and need special processing 
conditions to get a powder which fulfils the requirements for 3DP. Despite the above 
discussed restrictions, 3DP has been explored by several tissue engineering groups for more 
than a decade and a spin-off from MIT (Therics Inc., MA, USA) has commercialized 
scaffolds made by 3DP. 
 
More recently, several groups were able to print cells in combination with hydrogels 
by simple modification of office ink jet printers showing the proof-of-principle to one day 
have the capacity to build tissue engineered constructs in a fully automated system [129-131]. 
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8.1.3.3. Systems Based on Extrusion/ Direct Writing 
 
A number of groups have developed SFF machines that can perform extrusion of 
strands/filaments and/or plotting of dots in 3D with or without incorporation of cells [132, 
133]. These systems are built to make use of a wide variety of polymer hot-melts as well as 
pastes/slurries (i.e. solutions and dispersions of polymers and reactive oligomers). 
Techniques such as FDM, 3D-Plotting, Multiphase Jet Solidification and Precise Extrusion 
Manufacturing all employ extrusion of a material in a layered fashion to build a scaffold. 
Depending on the type of machine, a variety of biomaterials can be used for scaffold 
fabrication.  
 
Fused deposition modeling 
A traditional fused deposition modeling (FDM) machine (Figure 9i) consists of a 
head-heated-liquefier attached to a carriage moving in the horizontal x-y plane. The function 
of the liquefier is to heat and pump the filament material through a nozzle to fabricate the 
scaffold following a programmed-path which is based on CAD model and the slice 
parameters. Once a layer is built, the platform moves down one step in the z direction to 
deposit the next layer. Parts are made layer by layer with the layer thickness varying in 
proportion to the nozzle diameter chosen. FDM is restricted to the use of thermoplastic 
materials with good melt viscosity properties; cells or other theromosensitive biological 
agents cannot be encapsulated into the scaffold matrix during the fabrication process. 
 
Park et al have fabricated highly functionalized polymeric three-dimensional 
structures characterized by nano and microfibres for use as an extracellular matrix-like tissue 
engineering scaffold. A hybrid process utilizing direct polymer melt deposition (DPMD) and 
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an electrospinning method were employed together to obtain the structure. As depicted 
schematically in Figure 10. Each microfibrous layer of the scaffold was built using the 
DPMD process in accordance with computer-aided design modelling data considering some 
structural points such as pore size, pore interconnectivity and fibre diameter. Between the 
layers of the three-dimensional structure, PCL/collagen nanofibre matrices were deposited 
via an electrospinning process. To evaluate the fabricated scaffolds, chondrocytes were 
seeded and cultured within the developed scaffolds for 10 days, and the levels of cell 
adhesion and proliferation were monitored. The results showed that the polymeric scaffolds 
with nanofibre matrices fabricated using the proposed hybrid process provided favorable 
conditions for cell adhesion and proliferation. These conditions can be attributed to enhanced 
cytocompatibility of the scaffold due to surface nanotopography in the scaffold, chemical 
composition by use of a functional biocomposite, and an enlarged inner surface of the 
structure for cell attachment and growth [134]. 
 
A variation of FDM process, the so called “Precision Extruding Deposition” (PED) 
system, was developed and tested at Drexel University [135]. The major difference between 
PED and conventional FDM is that the scaffolding material can be directly deposited without 
filament preparation. Pellet formed PCL is fused by a liquefier temperature provided by two 
heating bands and respective thermal couples and is then extruded by the pressure created by 
a turning precision screw [136]. 
 
A design limitation of using an extrusion system in combination with thermoplastic 
polymers includes the fact that the pore openings for the scaffolds are not consistent in all 
three dimensions as observed. The pore openings facing the z-direction are formed in 
between the intercrossing of material struts/bars and are determined by user-defined 
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parameter settings. However, for pore openings facing both the x- and y-directions, these 
openings are formed from voids created by the stacking of material layers and hence, their 
sizes are restricted to the bar/strut thickness (diameter). As such, systems with a single 
extrusion head/liquefier do not exhibit variation in pore morphology in all 3 axes. A design 
variability exists by extruding one strut/bar directly on top of each other [136]. 
 
Direct writing 
In the material science literature another term for extrusion based systems is used, 
namely “Direct-write techniques” (Figure 9j). The techniques employed in direct writing are 
pertinent to many other fields next to scaffold fabrication such as the capability of controlling 
small volumes of liquid accurately. Direct-write techniques involving colloidal ink containing 
PCL can be divided into two approaches: droplet-based including direct ink-jet printing, hot-
melt printing and continuous (or filamentary) techniques. 
 
8.1.4. Surface Modification of PCL 
The purpose of surface modification is to retain the key bulk properties of the material 
while modifying the surface to improve biocompatibility. Typically, modifications can be 
either chemical or physical and can alter the compounds, or molecules on the existing 
surface, or may be achieved via coating the existing surface with a different material [137]. 
 
To functionalize PCL for bioconjugation, a chemical vapor deposition (CVD) 
polymerisation technique was utilized by Hu et al to modify material surfaces. Poly [(4-
amino-p-xylylene)-co-(p-xylylene)] (PPX-NH2) was deposited on inert PCL surfaces to 
provide a reactive amine layer on the substrate surfaces. The biocompatibility of PPX-NH2 
was evaluated with cells continuously proliferated on CVD treated PCL surfaces with high 
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survival rates. Biotin was conjugated on modified PCL surfaces to immobilize avidin for 
binding of biotinylated adenovirus. Scanning electron microscopy (SEM) examination 
illustrated that adenoviruses were evenly bound on both 2D films and 3D scaffolds; 
suggesting CVD was capable of modifying various substrates with different geometries. 
Using a wax masking technique, the biotin conjugation was controlled to immobilize avidin 
on specific sites. Due to the virus binding specificity on CVD-modified surfaces, cell 
transduction was restricted to the pattern of immobilized virus on biomaterials, by which 
transduced and non-transduced cells were controlled in different regions with a distinct 
interface. Because CVD was functional in different hierarchies, this surface modification 
should be able to custom-tailor bioconjugation for different applications [138]. 
 
Kim et al synthesised biocompatible photothermal agents using gold nanorod-
embedded polymeric nanoparticles, which were synthesized using a nanoprecipitation 
method. Uniform gold nanorods which were sensitive to a photothermal effect by near-
infrared were synthesized by a seed-mediated growth method. The hydroxyl groups of PCL 
diol were modified by esterification with mercaptopropionic acid to give PCL dithiol as a 
phase transfer and capping agent. Subsequently, hexadecyltrimethylammonium bromide was 
exchanged and/or removed by PCL dithiol. PCL dithiol-coated gold nanorods were further 
wrapped in a hydrophilic polymer, Pluronic F127, as a stabilizer. These newly formulated 
gold nanorods exhibited excellent stability in water and a maximum absorbance in the NIR 
region indicating a highly efficient surface plasmon resonance effect, phenomena useful for 
photothermal agents [139]. 
 
NaOH-treated PCL films are also investigated by Serrati et al for vascular tissue 
engineering by supporting the culture of primary vascular cells and endothelial-like EC2 cells 
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derived from endothelial progenitor cells. Results obtained demonstrated that EC2 seeded on 
NaOH-treated PCL films enhance the basal NO levels and showed a faster, more intense 
response to physiological stimuli such as VEGF, bradykinin and thrombin than vein 
endothelial cells. This could be indicative of a better capacity of EC2 cells to maintain their 
endothelial functionality when seeded on these polymers and reinforced the idea that 
endothelial-like EC2 cells derived from blood progenitors are an adequate source of 
endothelial cells to functionalize vascular grafts. Furthermore, NaOH-treated PCL films 
could be considered as a promising cellular NO production-inducing biomaterial for vascular 
tissue engineering applications [140]. 
 
PCL has been surface modified to possess a bone-like apatite layer bound to its 
surface as a scaffold for tissue engineering applications. The surface of PCL was treated with 
aqueous NaOH to introduce carboxylate groups onto the surface and was subsequently 
dipped in aqueous CaCl2 and K2HPO4·3H2O to deposit apatite nuclei on the surface. The 
surface-modified material successfully formed a dense and uniform bone-like surface apatite 
layer after incubation for 24 h in simulated body fluid with ion concentrations approximately 
equal to those of human blood plasma [141]. Yu et al also produced nanofibrous bone-like 
apatite-covered PCL using a similar technique. The surface of the mineralized PCL nanofibre 
was observed to be almost fully covered with nanocrystalline apatites and through 
mineralization, the wettability of the nanofibre matrix was greatly improved. Murine-derived 
osteoblastic cells were shown to attach and grow actively on the apatite-mineralized 
nanofibrous substrate. In particular, the mineralized PCL nanofibrous substrate significantly 
stimulated the expression of bone-associated genes, including Runx2, collagen type I, 
alkaline phosphatase, and osteocalcin, when compared with the pure PCL nanofibre substrate 
without mineralization [142]. 
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Proteins that contain the Arg-Gly-Asp (RGD) attachment site, together with the 
integrins that serve as receptors for them, constitute a major recognition system for cell 
adhesion to surfaces. The RGD sequence is the cell attachment site of a large number of 
adhesive ECM, blood, and cell surface proteins and various groups have investigated the 
immobilization of this sequence onto potential implants/scaffolds. Zhang et al established a 
simple method to immobilize the RGD peptide on PCL film surfaces that significantly 
improved bone marrow stromal cell adhesion to these films. They extended their 
modification strategy to three-dimensional PCL scaffolds to investigate cell responses to the 
modified RGD-PCL scaffolds compared to responses to the untreated ones. The results 
demonstrated that treatment of 3D PCL scaffold surfaces with 1,6-hexanediamine introduced 
the amino functional groups onto the porous PCL scaffold homogenously and followed by 
the cross-linking reaction, RGD peptide was successfully immobilized on the PCL surface. 
Although the static seeding method used in this study caused heterogeneous cell distribution, 
the RGD-modified PCL scaffold still demonstrated the improved BMSC attachment and 
cellular distribution in the scaffold. More importantly, the integrin-mediated signal 
transduction FAK-PI3K-Akt pathway was significantly up-regulated by RGD modification 
and a subsequent increase in cell survival and growth was found in the modified scaffold. The 
study concluded that modification of 3D PCL scaffolds with RGD peptides elicits specific 
cellular responses and improves the final cell-biomaterial interaction [143]. 
 
Tissues engineered from biological cell sheets often lack substrate cues and possess 
poor mechanical strength hence Chong et al used micro-thin, biaxially-stretched PCL with 
surface modifications for layered tissue engineering. Polyacrylic acid was grafted onto PCL 
film surfaces by low-pressure plasma immobilisation which provided a surface suitable for 
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perivascular cells, forming the medial compartment of a biphasic cell-sheet. Subsequently, 
endothelial progenitor cell-selective CD34 antibody was conjugated onto the reverse surface 
(intimal compartment) to select and anchor endothelial progenitor cells for improved 
adhesion and proliferation. Using the blood vessel as a model, a biphasic culture system was 
then setup to represent a tunica intima (endothelial cells) and tunica media (smooth muscle 
cells). When suitable cell types were cultured in the corresponding compartments, confluent 
layers of the respective populations were achieved distinctively from each other. These 
results demonstrate the use of micro-thin, biaxially-stretched PCL films with cell-selective 
modifications for layered co-cultures towards the generation of stratified tissue [144]. 
 
Lu et al used coaxial electrospinning to immobilize bioactive agents into PCL fibres. 
Gelatin was cationized by derivation with N,N-dimethylethylenediamine and was used as a 
shell material for constructing a core-shell fibrous membrane. PCL formed the core section of 
the core-shell fibres thereby improving the mechanical properties of nanofibrous hydrogel. 
The outer layer was crosslinked by exposing the membranes in glutaraldehyde vapor. The 
adsorption behaviors of FITC-labeled bovine serum albumin (FITC-BSA) or FITC-heparin 
onto the fibres were then investigated. The core-shell fibres could effectively immobilize the 
two types of agents under mild conditions. Furthermore, vascular endothelial growth factor 
could be conveniently impregnated into the fibres through specific interactions with the 
adsorbed heparin in the outer CG layer. Sustained release of bioactive VEGF was also 
achieved for more than 15 days [145]. 
 
 There are a vast array of manufacturing techniques to create scaffolds for tissue 
engineering, but one must pay special attention to the scaffold specifications and understand 
the huge interplay of factors affecting the design criteria. The desirable feature of any 
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implantable polymeric scaffold material would be synchronization of polymer degradation 
with the replacement by natural tissue produced from cells as previously described and 
illustrated graphically in Figure 8.  In the following section the tissue engineering areas in 
which PCL scaffolds have been applied are comprehensively discussed. 
 
8.2. Bone Engineering 
 Potential bone tissue scaffolds are under investigation by Thomas et al who have 
undertaken a mechanical and morphological study of electropun, aligned PCL nanofibre 
meshes produced at different collector rotation speeds (0, 3000, 6000 rpm). They noted 
higher alignments and tensile strengths with increasing rotation speeds, whereas, conversely, 
they showed lower hardness and young’s modulus with increasing rotation speeds. These 
properties were attributed, microscopically and macroscopically to the crystallinity of the 
fibres and better alignment/tighter packing density. This study highlights the need to 
investigate individual parameters of a production process to gain optimised mechanical 
properties for a specific application [146]. 
 
 Choi et al electrospun PCL/collagen nanofibres of different orientations, to engineer 
functional muscle tissue for restoring large skeletal muscle tissue defects. Human skeletal 
muscle cells were cultured on these substrates. Unidirectionally oriented nanofibres 
significantly induced muscle cell alignment and myotubule formation compared to random 
orientations of nanofibres [124]. 
 
 PCL cylindrical scaffolds with gradually increasing pore size along the longitudinal 
direction were fabricated by a novel centrifugation method to investigate pore size effect on 
cell and tissue interactions. The scaffold was fabricated by the centrifugation of a cylindrical 
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mould containing fibril-like PCL and the following fibril bonding by heat treatment as 
depicted schematically in Figure 11 [147]. The scaffold showed gradually increasing pore 
size (from ~88 to ~405µm and porosity (from ~80% to ~94%) along the cylindrical axis by 
applying the centrifugal speed, 3000 rpm. The scaffold sections were examined for their in 
vitro cell interactions using different kinds of cells (chondrocytes, osteoblasts, and 
fibroblasts) and in vivo tissue interactions using a rabbit model (skull bone defects) in terms 
of scaffold pore sizes. It was observed that different kinds of cells and bone tissue were 
shown to have different pore size ranges in the scaffold for effective cell growth and tissue 
regeneration. The scaffold section with 380-405µm pore size showed better cell growth for 
chondrocytes and osteoblasts, while the scaffold section with 186-200µm pore size was better 
for fibroblasts growth. Also the scaffold section with 290-310 µm pore size showed faster 
new bone formation than those of other pore sizes. The pore size gradient scaffolds fabricated 
by this centrifugation method might be considered a good tool for the systematic studies of 
interactions between cells or tissues and scaffolds with different pore sizes [147]. 
 
 Composite scaffolds with well-organized architecture and multi-scale porosity for 
achieving a tissue engineered construct to reproduce the middle and long-term behaviour of 
hierarchically complex tissues such as spongy bone has been investigated utilising fibre-
reinforced composites. Scaffolds comprising PLLA fibres embedded in a porous PCL matrix 
were obtained by synergistic use of phase inversion/particulate leaching technique and 
filament winding technology. Porosities of up to 80% were achieved, with pore sizes of 
between 10 and 200 µm diameter. In vitro degradation was carried out in PBS without 
significant degradation of the scaffold after 35 days, whilst in NaOH solution, a linear 
increase of weight lost was observed with preferential degradation of the PLLA component. 
Upon cell seeding, marrow stromal cells and human osteoblasts reached a plateau at 3 weeks, 
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and at 5 weeks the number of cells was almost the same. Human marrow stromal cells and 
trabecular osteoblasts rapidly proliferated on the scaffold up to 3 weeks, promoting an 
oriented migration of bone cells along the fibre arrangement. The novel PCL/PLLA 
composite scaffold was concluded to show promise whenever tuneable porosity, controlled 
degradability and guided cell-material interaction are simultaneously required [148]. 
 
 A bioactive and bioresorbable scaffold fabricated from medical grade PCL (mPCL) 
and incorporating 20% beta-tricalcium phosphate (mPCL-TCP) which has been well 
characterised studied by Hutmacher et al, has been further developed for bone regeneration at 
load bearing sites by Abbah et al [149]. Bone in-growth into mPCL-TCP in a large animal 
model of lumbar interbody fusion was evaluated using six pigs, each undergoing a 2-level 
(L3/4; L5/6) anterior lumbar interbody fusion and implanted with mPCL-TCP scaffolds 
+0.6mg rhBMP-2 as treatment group while four other pigs implanted with autogenous bone 
graft, which served as control. µCT scanning and histology revealed complete defect bridging 
in all (100%) specimens from the treatment group as early as 3 months. Histological evidence 
of continuing bone remodelling and maturation was observed at 6 months. In the control 
group, only partial bridging was observed at 3 months and only 50% of segments in this 
group showed complete defect bridging at 6 months. Furthermore, 25% of segments in the 
control group showed evidence of graft fracture, resorption and pseudoarthrosis. In contrast, 
no evidence of graft fractures, pseudoarthrosis or foreign body reaction was observed in the 
treatment group. These results reveal that mPCL-TCP scaffolds could act as bone graft 
substitutes by providing a suitable environment for bone regeneration in a dynamic load 
bearing setting such as in a porcine model of interbody spine fusion [149]. 
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 Bone research at the National University of Singapore based on medical grade PCL 
both in vitro and in vivo was commercialised after clinical approval in 2008 (Osteopore™). 
 
 Artlelon® is a unique patented biomaterial comprising polycaprolactone-based 
polyurethane which acts as a temporary support to the healing tissue; approximately half of 
the implant is comprised from PCL. Artelon® can be made to fibres, scaffolds and films and 
be used in a number of orthopedic applications and in other therapy areas. The hydrolysis 
results in a resorbable (PCL) and a non-resorbable poly(urethane-urea) fraction. The 
degradation products have been proven to be safe and tissue compatible and do not generate 
an acidic environment. When the hydrolysis of the ester bonds from the PCL component is 
completed about 50% of the initial mass remains at the implantation site and the remaining 
material is incorporated in the surrounding host tissue without eliciting any inflammatory or 
foreign body response  [150]. The Artelon® CMC Spacer Arthro is a T-shaped device, where 
vertical portion separates the trapezial and the metacarpal bone of the carpometacarpal joint.  
 
8.3. Cartilage Engineering 
 Cartilage degeneration caused by congenital abnormalities or disease and trauma is of 
great clinical consequence, given the limited intrinsic healing potential of the cartilage tissue. 
The lack of blood supply and subsequent wound-healing response, damage to cartilage alone, 
or chondral lesions, leads to an incomplete attempt at repair by local chondrocytes. Full-
thickness articular cartilage damage, or osteochondral lesions, allow for the normal 
inflammatory response, but result in inferior fibrocartilage formation. To prevent progressive 
joint degeneration in diseases such as osteoarthritis, surgical intervention is often the only 
option. In spite of the success of total joint replacement, treatments for repair of cartilage 
damage are often less than satisfactory, and rarely restore full function or return the tissue to 
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its native normal state. Tissue engineering aims to address this challenge through 
development of a biocompatible, structurally and mechanically sound scaffold, with an 
appropriate cell source, which may be loaded with bioactive molecules that promote cellular 
differentiation and/or maturation[151] 
 
 Huang et al developed a biphasic implant made comprising PCL with TGF-β1-loaded 
fibrin glue to determine whether the implant could recruit mesenchymal cells and induce the 
process of cartilage formation when implanted in ectopic sites. PCL scaffolds loaded with 
various doses of TGF-β1 in fibrin glue were implanted subcutaneously, intramuscularly, and 
subperiosteally and assessed histologically 2, 4, and 6 weeks postoperatively. The entire pore 
spaces of the scaffolds were filled with various tissues in each group. The entire volume of 
the scaffolds in the groups loaded with TGF-β1 and implanted intramuscularly and 
subcutaneously was populated with mesenchymal cells surrounded with an abundant 
extracellular matrix and blood vessels. The scaffold loaded with TGF-β1 and implanted 
subperiosteally was found to be richly populated with chondrocytes at 2 and 4 weeks and 
immature bone formation was identified at 6 weeks. The study concluded that scaffolds 
loaded with TGF-β1 could successfully recruit mesenchymal cells and that chondrogenesis 
occurred when this construct was implanted sub-periosteally [152]. 
 
 Nanofibrous materials, by virtue of their morphological similarities to natural 
extracellular matrix, have been considered as candidate scaffolds for cell delivery in tissue-
engineering applications. Several studies have used electrospinning techniques to fabricate 
nanofibrous materials for cartilage tissue engineering applications [153] [154]. 
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 Three-dimensional, nanofibrous PCL scaffolds were assessed by Li et al for their 
ability to maintain chondrocytes in a mature functional state. Fetal bovine chondrocytes 
(FBCs) were seeded onto three-dimensional biodegradable PCL nanofibrous scaffolds or as 
monolayers on standard tissue culture polystyren as a control substrate. Gene expression 
analysis showed that chondrocytes seeded on the nanofibrous scaffold and maintained in 
serum-free medium supplemented with ITS+, ascorbate, and dexamethasone continuously 
maintained their chondrocytic phenotype by expressing cartilage-specific extracellular matrix 
genes, including collagen types II and IX, aggrecan, and cartilage oligomeric matrix protein. 
Specifically, expression of the collagen type IIB splice variant transcript, which is indicative 
of the mature chondrocyte phenotype, was up-regulated. FBCs exhibited either a spindle or 
round shape on the nanofibrous scaffolds, in contrast to a flat, well-spread morphology seen 
in monolayer cultures on tissue culture polystyrene. Histologically, nanofibrous cultures 
maintained in the supplemented serum-free medium produced more sulfated proteoglycan-
rich, cartilaginous matrix than monolayer cultures. In addition to promoting phenotypic 
differentiation, the nanofibrous scaffold also supported cellular proliferation as evidenced by 
a 21-fold increase in cell growth over 21 days when the cultures were maintained in serum-
containing medium. These results indicated that the biological activities of FBCs are crucially 
dependent on the architecture of the extracellular scaffolds as well as the composition of the 
culture medium, and that nanofibrous PCL acts as a biologically preferred scaffold/substrate 
for proliferation and maintenance of the chondrocytic phenotype thus being a suitable 
candidate scaffold for cartilage tissue engineering [155]. 
 
Wise et al electrospun oriented PCL scaffolds (500 or 3000nm fibre diameter) onto 
which they seeded human mesenchymal stem cells. Cell viability, morphology, and 
orientation on the fibrous scaffolds were quantitatively determined as a function of time. 
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While the fibre-guided initial cell orientation was maintained even after 5 weeks, cells 
cultured in the chondrogenic media proliferated and differentiated into the chondrogenic 
lineage, suggesting that cell orientation is controlled by the physical cues and minimally 
influenced by the soluble factors. Based on assessment by chondrogenic markers, they 
concluded that use of the nanofibrous scaffold (500 nm) enhanced chondrogenic 
differentiation and indicate that hMSCs seeded on a controllable PCL scaffold may lead to an 
alternate methodology to mimic the cell and ECM organization [156]. 
 
 To evaluate the repair potential in large osteochondral defects on high load-bearing 
sites, Shao et al fabricated a hybrid scaffold system which comprised 3D porous PCL 
scaffold for the cartilage component and tricalcium phosphate-reinforced PCL scaffold for 
the bone portion. Osteochondral defects of 4-mm diameter X 5.5- mm depth were created in 
the medial femoral condyle of adult New Zealand White rabbits. The defects were treated 
with hybrid scaffolds without cells (control group) or seeded with allogenic bone marrow - 
derived mesenchymal stem cells (BMSC) in each part (experimental group) by press-fit 
implantation. Implanted cells were tracked using Adeno-LacZ labelling and tissues were 
evaluated at 3 and 6 months after implantation. Overall, the experimental group showed 
superior repair results as compared to the control group using gross examination, qualitative 
and quantitative histology, and biomechanical assessment. With BMSC implantation, the 
hybrid scaffolds provided sufficient support to new osteochondral tissue formation and the 
bone regeneration was consistently good from 3 to 6 months, with firm integration to the host 
tissue. Cartilage layer resurfacing was considered more complicated with all of the samples 
presenting cartilage tissues mixed with PCL scaffold filaments at 3 months. Histology at 6 
months revealed some degradation phenomenon in several samples whereas others had a 
good appearance; however, the Young's moduli from the experimental group (0.72 MPa) 
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approached that of normal cartilage (0.81 MPa). In vivo viability of implanted cells was 
demonstrated by the retention for 6 weeks in the scaffolds. The authors concluded that this 
study indicated the promise of PCL-based hybrid scaffolds seeded with BMSC as an 
alternative treatment for large osteochondral defects in high-loading sites [157]. 
 
In another study, Li et al evaluated cell-seeded nanofibrous PCL scaffolds for 
cartilage repair using 7 mm full-thickness cartilage defects in a swine model. They utlised 
allogeneic chondrocytes or xenogeneic human mesenchymal stem cells (MSCs), with 
acellular PCL scaffolds and empty defects as control groups. Six months after implantation, 
MSC-seeded constructs showed the most complete repair in the defects compared to other 
groups. Macroscopically, the MSC-seeded constructs regenerated hyaline cartilage-like tissue 
and restored a smooth cartilage surface, while the chondrocyte-seeded constructs produced 
mostly fibrocartilage-like tissue with a discontinuous superficial cartilage contour. 
Incomplete repair containing fibrocartilage or fibrous tissue was found in the acellular 
constructs and the empty defects. Quantitative histological evaluation showed overall higher 
scores for the chondrocyte- and MSC-seeded constructs than the acellular construct and the 
no-implant groups. Mechanical testing showed the highest equilibrium compressive stress of 
1.5 MPa in the regenerated cartilage produced by the MSC-seeded constructs, compared to 
1.2 MPa in the chondrocyte-seeded constructs, 1.0 MPa in the acellular constructs and 0.2 
MPa in the no-implant group. No evidence of immune reaction to the allogeneically- and 
xenogeneically-derived regenerated cartilage was observed, possibly related to the 
immunosuppressive activities of MSCs, suggesting the feasibility of allogeneic or xenogeneic 
transplantation of MSCs for cell-based therapy. The collective summary from this work was 
to show that biodegradable nanofibrous scaffolds seeded with MSCs could effectively repair 
cartilage defects in vivo, and that this approach is promising for cartilage repair [158]. 
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 A composite scaffold comprising a PCL stent and a type II collagen sponge for tissue-
engineered trachea was developed by Lin et al. The PCL stent had surface grooves which 
were filled by the type II collagen with crosslinking treatment producing a ring-shaped 
collagen sponge. Rabbit chondrocytes (3x106 cells per ring) were seeded onto the collagen 
sponge of the scaffold and the cell-scaffold constructs were then implanted subcutaneously in 
the dorsum of nude mice. After 4 and 8 weeks, constructs were harvested and analysed for 
mechanical properties, histology, and biochemical assays. Constructs were strong enough to 
retain their tubular shape against extrinsic forces in the dorsum of nude mice and the gross 
appearance of the constructs revealed cartilage-like tissue at 8 weeks, with a modulus higher 
than that of native trachea. Histological and biochemical analyses of the tissue-engineered 
tracheal cartilage revealed evenly spaced lacunae embedded in the matrix, with abundant 
proteoglycans and type II collagen. The stent-sponge composite facilitated the proliferation of 
chondrocytes and was expected to provide adequate mechanical strength in possible future 
applications in trachea tissue engineering [159]. 
 
 Meniscal tissue engineering has been investigated using hyaluronic acid/PCL to 
evaluate the tissue regeneration after the augmentation of the implant with expanded 
autologous chondrocytes. Twenty-four skeletally mature sheep were treated with total medial 
meniscus replacements, while two meniscectomies served as empty controls. The animals 
were divided into two groups: cell-free scaffold and scaffold seeded with autologous 
chondrocytes. Two different surgical techniques were compared: in 12 animals, the implant 
was sutured to the capsule and to the meniscal ligament; in the other 12 animals, also a trans-
tibial fixation of the horns was used. The animals were euthanized after 4 months and 
specimens were assessed by gross inspection and histology. All implants showed excellent 
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capsular in-growth at the periphery. Macroscopically, no difference was observed between 
cell-seeded and cell-free groups. Better implant appearance and integrity was observed in the 
group without transosseous horns fixation. Using the latter implantation technique, lower 
joint degeneration was observed in the cell-seeded group with respect to cell-free implants. 
Histological analysis indicated cellular infiltration and vascularization throughout the 
implanted constructs with cartilaginous tissue formation being significantly more frequent in 
the cell-seeded constructs. The study supports the potential of a novel hyaluronic acid /PCL 
scaffold for total meniscal substitution, and furthermore, seeding of the scaffolds with 
autologous chondrocytes provided some benefit in the extent of fibrocartilaginous tissue 
repair [160]. 
 
 
8.4. Tendon & Ligament Engineering 
 Tendon reconstruction with PCL films using a rat model has been attempted with 
good functional recovery. PCL films were prepared by solvent casting and used for repair of 
gaps in Achilles tendons in a rat model. Five groups were studied; (i) sham operated (skin 
incision only); (ii) no repair (complete division of the Achilles tendon and plantaris tendon 
without repair); (iii) Achilles repair (with a modified Kessler type suture); and (iv) plasty of 
Achilles tendon defects with the biodegradable PCL films, and (v) animals subjected to 1cm, 
mid-substance defect with no repair. Functional performance was determined from the 
measurements of hindpaw prints utilizing the Achilles functional index. The animals were 
euthanized  8 weeks after surgery and histological and biomechanical evaluations were made. 
All groups subjected to Achilles tendon division had a significant functional impairment that 
gradually improved so that by day 28 there were no functional impairments in any group 
whereas animals with a defect remained impaired [146]. 
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 Artelon® Tissue Reinforcement/SportMesh™ are patches comprising PCL-based 
polyurethane which is sutured over ruptured tissue as reinforcement when repairing a torn 
tendon. The degradable Artelon® implant maintains its strength and elasticity over several 
years providing long term support of the soft tissue while being a scaffold for tissue in-
growth and remodeling. The implant has been shown to partially degrade. The remaining 
material is incorporated into the patient’s surrounding tissue, and intended to strengthen weak 
or repaired tissue [150]. 
 
 Mesofol® is a transparent, absorbable film that can be inserted between muscles, 
muscles and tendons or nerves to prevent postoperative adhesion. The basic materials of the 
medical device are lactide and caprolactone. Mesofol® can also take over the fascia's sliding 
function, improving the physiologic free gliding and thus reducing postoperative pain and 
preventing negative effects due to tissue conglutination [161]. 
 
 
8.5. Cardiovascular engineering 
The main failings of presently available mechanical or biological valve prostheses are 
thrombogenicity and poor durability. Tissue engineering has being used to provide a valve 
that does not have these disadvantages and is able to grow, repair, and remodel. Most of the 
replaced valves are mitral or aortic, so tissue engineering of the aortic valve is a challenge 
that, once met, will lead to a very useful product. To create a tissue-engineered aortic valve, a 
strong scaffold is a prerequisite. The scaffold on which cells are seeded is important in giving 
the specific valvular shape to the growing tissue, guiding the development of the tissue and 
providing support against mechanical forces. Since the opted tissue is ideally completely 
autologous, the scaffold should be biodegraded, leaving cells and extracellular matrix 
components that have developed into fully autologous tissue. 
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Van Lieshout et al developed two types of scaffolds for tissue engineering of the 
aortic valve; an electrospun valvular scaffold and a knitted valvular scaffold. These scaffolds 
were compared in a physiologic flow system and in a tissue-engineering process. In fibrin gel 
enclosed human myofibroblasts were seeded onto both types of scaffolds and cultured for 23 
days under continuous medium perfusion. Tissue formation was evaluated by confocal laser 
scanning microscopy, histology and DNA quantification. Collagen formation was quantified 
by a hydroxyproline assay. When subjected to physiologic flow, the spun scaffold tore within 
6 h, whereas the knitted scaffold remained intact. Cells proliferated well on both types of 
scaffolds, although the cellular penetration into the spun scaffold was poor. Collagen 
production, normalized to DNA content, was not significantly different for the two types of 
scaffolds, but seeding efficiency was higher for the spun scaffold, because it acted as a cell 
impermeable filter. The knitted tissue constructs showed complete cellular in-growth into the 
pores. They concluded that an optimal scaffold seems to be a combination of the strength of 
the knitted structure and the cell-filtering ability of the spun structure [123, 162]. Figure 12 
shows the PCL knitted valve and a porcine stent-less valve prosthesis inside a physiological 
flow simulator.  
 
Gene therapy approaches to treat heart conditions have also utlised PCL as a release 
reservoir in a similar fashion to micro/nanosphere drug delivery systems. Wang et al 
developed a gene therapy system to treat hypertension and/or congestive heart failure based 
on the release of atrial natriuretic peptide (ANP) from ANP-cDNA-transfected Chinese 
Hamster Ovary cells which had been encapsulated within PCL tubes. The encapsulated cells 
remained viable during culture and ANP secretion was maintained for at least 6 months 
[163]. 
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Electrospun sheets comprising PCL with different fibre diameters (3-12 µm) were 
investigated for penetration depth using human venous myofibroblastsas as a means to 
optimize cell delivery during cardiovascular tissue engineering applications. Optimal cell 
delivery was observed using the largest diameter fibres (12 µm) highlighting the importance 
of optimizing the electrospun scaffold geometry for specific cell types [164]. 
 
 Shape memory materials have been proposed for cardiovascular stents due to their 
self-expansion ability. The most ideal way to anchor a stent is using self-expansion in the 
range of body temperature. Ajili et al use have utilised a polyurethane/PCL blend as a 
proposed material for shape memory stents. Polyurethane copolymer based on PCL diol was 
melt blended with PCL in four different ratios of 20, 30, 40 and 50 wt.% and their shape 
memory behaviors were examined. All blends except for 80/20 showed shape memory effects 
with recovery temperatures of around the melting temperature of PCL in the blends. The 
melting behavior of the PCL in the blends was strongly influenced by composition. Changing 
the composition of the blend system and crystallization conditions adjusted shape recovery to 
the range of body temperature for PU/PCL 70/30 blend. The in vitro biocompatibility of 
70/30 blend was further evaluated using human bone marrow mesenchymal stem cells and 
assessing cell adhesion, morphology and mitochondrial function. The results showed that the 
blend supported cell adhesion and proliferation, which indicated good biocompatibility in 
addition to shape memory properties, providing potential use as a stent implant [165]. 
 
 
8.6. Blood Vessel Engineering 
There has been significant research regarding the effects of scaffold surface chemistry 
and degradation rate on tissue formation and the importance of these parameters is widely 
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recognised. In addition to these important factors are considerations of elastic properties. 
Several studies describing the role of mechanical stimuli during tissue development and 
function suggest that the mechanical properties of the scaffold are also important. Cyclic 
mechanical strain has been demonstrated to enhance the development and function of 
engineered smooth muscle tissues, and it would be necessary for the development of elastic 
scaffolds if one wishes to engineer smooth tissues under cyclic mechanical loading. 
Biodegradable polyesters, such as PGA, PLA and PLGA, although commonly used in tissue 
engineering, undergo plastic deformation and failure when exposed to long-term cyclic strain, 
limiting their use in engineering elastomeric tissues and thus composites and copolymers 
have been investigated to circumvent this issue [166]. 
 
Lee et al developed an elastic polymer fabricated from poly(glycolide-co-
caprolactone) (PGCL) using solvent casting and particle-leaching techniques. The 
demonstrated superior elastic properties (extension and recovery, permanent deformation) 
compared with PLGA equivalents with good promise as smooth muscle-containing tissue 
candidates [167]. 
 
Jeong et al have developed tubular, elastic biodegradable poly(lactide-co-
caprolactone) (PLCL) for mechano-active vascular tissue engineering. They demonstrated 
very flexible, rubber-like elastic with 200% elongation and over 85% recovery in tension. 
Moreover, under cyclic mechanical strain conditions in culture media,they maintained their 
high elasticity. Vascular smooth muscle cells showed good cell adhesion and proliferation on 
the scaffolds, responding optimally to the porosities of 200-250 µm, compared with the lower 
ranges between 50 and 200 µm. The in vivo biocompatibility was also established in a 
subcutaneous mouse model. The conclusion was a promising composite/copolymer elastic 
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material for the engineering of smooth muscle containing tissues such as blood vessels under 
mechanically dynamic environments [167, 168]. 
 
 In vivo vascular smooth muscle cells typically reside in mechanically dynamic 
environments, align in a specific direction and exist in a contractile, differentiated phenotype 
which is critical for the contractile functions of smooth muscle cells [169]. A drawback of 
conventional in vitro tissue engineering is the possibility of smooth muscle reverting to a 
non-differentiated phenotype (non aligned and non contractile). A number of studies have 
demonstrated that the addition of cyclic strains and pulsatile flow in 2D or 3D culture 
systems gives superior smooth muscle cell responses with enhanced mechanical strength and 
collagen/elastin production [170, 171]. For such a mechano-active system, the scaffold used 
must be able to deliver mechanical stresses to adhered cells and materials such as PGA have 
non-elastic properties and are unsuitable for these applications. Initial studies by Kim et al 
using PLA and PGA scaffolds resulted in significant permanent deformation under cyclic 
mechanical strain conditions [172]. They next developed a mechano-active polymer 
comprising 50 wt% hard domains of L-lactide units with 50 wt% soft domain of caprolactone 
moeities (PLCL), this copolymer system exhibited rubber-like elasticity and could be 
fabricated into scaffolds via a variety of techniques [168, 173-177]. The superior elastic 
properties of these scaffolds are depicted in Figure 13. PLCL scaffolds with a 90% porosity 
showed 100% recovery at near 100% strain (Figure 13a-c). Furthermore, PLCL scaffolds 
could be easily twisted and bent (Figure 13c-e), in contrast the PLGA scaffolds largely 
deformed and were broken at low strains (20%) (Figure 13f). The study concluded the 
scaffolds to be highly flexible and elastic and suitable for vascular tissue engineering 
applications. This PLCL mechano-active scaffold has also shown potential use in cartilage 
engineering applications [178-180]. 
 
 
70
 
 A three-layered robust and elastic artery was fabricated by Iwasaki et al using PGA 
and PCL sheets seeded with endothelial cells, smooth muscle cells and fibroblasts followed 
by culture in a novel hemodynamically-equivalent pulsatile bioreactor. The seeded-sheets 
were wrapped on a 6-mm diameter silicone tube and incubated in culture medium for 30 days 
after which the supporting tube was removed. The pulsatile bioreactor culture, under 
regulated gradual increase in flow and pressure from 0.2 (0.5/0) L/min and 20 (40/15) mm 
Hg to 0.6 (1.4/0.2) L/min and 100 (120/80) mm Hg, was performed for an additional 2 weeks 
(n=10). The engineered vessels acquired distinctly similar appearance and elasticity as native 
arteries. Scanning electron microscopic examination and Von Willebrand factor staining 
demonstrated the presence of endothelial cells spread over the lumen. Elastin and collagen 
were seen in in the engineered grafts and smooth muscle cells were detected. Tensile tests 
demonstrated that engineered vessels acquired equivalent ultimate strength and similar elastic 
characteristics as native arteries (Ultimate Strength of Native: 882+/-133 kPa, Engineered: 
827+/-155 kPa, each n=8). The small-diameter arteries produced from three types of vascular 
cells using the physiological pulsatile bioreactor were concluded to be robust and elastic 
[181]. 
 
 Recently there has been research focus on sutureless tissue fusion, to handle the limits 
of conventional suturing such as vascular wall damage due to the penetrating needle, 
intraluminal foreign body reactions caused by non-absorbable suture material and 
thrombocyte aggregation, and impaired endothelial function. Sutured wounds also have 
greater and longer duration inflammatory response than laser soldered wounds. Furthermore 
suturing does not create a watertight connection, which can, for example, in visceral surgery 
lead to an entry for pathogens resulting in severe complications such as infections or death 
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Bregy et al investigated the use of fused diode laser soldering of vascular tissue using PCL 
scaffolds doped with bovine serum albumin (BSA) and Indocyanine green (ICG) which 
concluded with strong and reproducible tissue bonds, with vessel damage limited to the 
adventitia [182]. Other approaches to tissue adhesives include the development of 
biocompatible tissue adhesives that do not involve any chemical or biochemical reactions, 
during their application in vivo; their use being based exclusively on their temperature-
dependent rheological properties. Branched oligomers consisting of a core molecule with 
biodegradable chains bound, and the relationship between their composition and their 
adhesive properties under in vitro conditions, was investigated by Cohn et al. The oligomers 
comprised trimethylolpropane as the trifunctional central molecule, while lactoyl and 
caprolactone units formed the biodegradable segments. Oligomers with glass transition 
temperatures, in the 20-25ºC range, were found to perform better. A strong connection was 
found between the length of the PLA blocks, the glass transition temperature of the different 
materials and their Adhesive Failure Strength at 37 ºC. The remarkable flexibilizing effect of 
the caprolactone units incorporated along the PLA blocks, allowed to generate longer 
biodegradable chains, and to improve, therefore, the adhesive strength of the oligomers, while 
keeping their Tg within the appropriate temperature interval [183]. 
 
 Bennan et al evaluated the growth potential of a tissue-engineered autologous 
vascular graft for pediatric cardiothoracic surgery in a juvenile animal model. PGA 
nonwoven mesh tubes (3-cm length, 1.3-cm id; Concordia Fibres) coated with a 10% 
copolymer solution of 50:50 PLLA and PCL were statically seeded with 1 x 106 cells/cm2 
autologous bone marrow derived mononuclear cells and were implanted as inferior vena cava 
interposition grafts in juvenile lambs. After 6 months implantation, neotissue was 
characterized using qualitative histological and immunohistochemical staining and 
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quantitative biochemical analysis. All grafts were patent and increased in volume as 
measured by difference in pixel summation in magnetic resonance angiography. The volume 
of seeded grafts at explant averaged 126.9% +/- 9.9% of their volume at 1 month. Magnetic 
resonance imaging demonstrated no evidence of aneurysmal dilation. The tissue-engineered 
vascular graft resembled the native inferior vena cava histologically and had comparable 
collagen and glycosaminoglycan contents. Immunohistochemical staining and Western blot 
analysis showed that Ephrin-B4, a determinant of normal venous development, was acquired 
in the seeded grafts 6 months after implantation, collectively providing good evidence of 
growth and venous development when implanted in a juvenile lamb model [184]. 
 
8.6.1. Electrospinning in Blood Vessel Engineering 
Multi-layering electrospinning techniques have been employed to develop a scaffold 
architecture mimicking morphological and mechanical features of a blood vessel (Figure 14). 
Bi-layered tubes comprising PLA/PCL were investigated and shown to support 3T3 mouse 
fibroblasts and human venous myofibroblasts which attached, proliferated and produced 
extracellular matrix over a 4 week culture period. The scaffolds also demonstrated desirable 
pliability (elastic up to 10% strain) [185]. 
 
Pektok and co-workers investigated the degradation and healing characteristics of 
small diameter PCL vascular grafts, produced via electrospinning, in the rat systemic arterial 
circulation. 2mm internal diameter grafts were produced and implanted for 24 weeks. Results 
concluded faster endothelialization and extracellular matrix formation, accompanied by 
degradation of graft fibres, compared with polytetrafluoroethylene grafts. The study 
concluded that healing characteristics of PCL may potentially lead to the clinical use of such 
grafts for revascularization procedures [186]. 
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Scaffolds for vascular tissue engineering are limited by issues of inconsistency, poor 
adherence of vascular cells, or inadequate biomechanical properties. Studies using 
electrospun  PCL/collagen scaffolds were shown to support adherence and growth of vascular 
cells under physiologic conditions and that endothelialized grafts resisted adherence of 
platelets when exposed to blood whilst maintaining their structural integrity and patency in a 
rabbit aortoiliac bypass model over 1 month of implantation. Further, at retrieval, these 
scaffolds continued to maintain biomechanical strength that was comparable to native artery, 
which indicates that electrospun PCL/collagen scaffolds combined with vascular cells may 
become an alternative to prosthetic vascular grafts for vascular reconstruction [187]. 
 
Electrospinning permits fabrication of biodegradable elastomers into matrices that can 
resemble similar mechanical properties as the native extracellular matrix. However, achieving 
high-cellular density and infiltration of scaffolds made from this technique remains 
challenging and time consuming. Stankus et al have overcome this limitation by 
electrospraying vascular smooth muscle cells (SMCs) concurrently with electrospinning a 
biodegradable, elastomeric poly(ester urethane)urea (PEUU). Trypan blue staining revealed 
no significant decrease in cell viability from the fabrication process and electrosprayed SMCs 
spread and proliferated similar to control unprocessed SMCs. PEUU was strong, flexible and 
anisotropic with tensile strengths ranging from 2.0 to 6.5 MPa and breaking strains from 850 
to 1700% dependent on the material axis. The ability to microintegrate smooth muscle or 
other cell types into a biodegradable elastomer fibre matrix embodies a novel tissue 
engineering approach that could be applied to fabricate high cell density elastic tissue 
mimetics, blood vessels or other cardiovascular tissues [188]. 
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8.7. Skin Engineering 
Engineered human skin is often fabricated using collagen scaffolds which are 
associated with poor mechanical properties. Powell et al blended PCL with collagen before 
electrospinning the composite to form submicron fibres. Tensile testing indicated that the 
inclusion of PCL from 10-100% significantly improved the strength and stiffness of the 
acellular scaffold. However, epidermal formation and reduced cell viability was evident at 
when the PCL content was increased beyond 10% and there was an associated loss of 
engineered skin construct strength indicating that high cell viability and proper development 
of the epidermis and important factors for developing engineered skin with high strength 
[189].  
 
Studies by Dai et al produced PCL/collagen composites for tissue engineered skin 
substitutes and demonstrated good cell attachment and proliferation of fibroblasts and 
keratinocytes [190]. They next utilised PCL/collagen blends as skin substitutes through 
seeding human single-donor keratinocytes and fibroblasts alone on both sides of the 1:20 
biocomposite to allow for separation of two cell types and preserving cell signals 
transmission via micro-pores with a porosity of 28.8 ± 16.1 [mu]m. The bi-layered skin 
substitute exhibited both differentiated epidermis and fibrous dermis in vitro. Less 
Keratinocyte Growth Factor production was measured in the co-cultured skin model 
compared to fibroblast-alone condition indicating a favorable microenvironment for 
epidermal homeostasis. Moreover, fast wound closure, epidermal differentiation, and 
abundant dermal collagen deposition were observed in composite skin in vivo [191]. 
 
 Composite tissue engineering has been investigated by Reed et al, using several cell-
types (human foreskin fibroblasts, murine keratinocytes and periosteal cells) cultured 
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together on PCL nanofibres. The aim was to produce trilaminar constructs, to reflect a 
compound tissue, although clear obstacles exist in maintaining an appropriate interface 
between the tissue types and neovascularisaion of the composite structure [192]. 
 
A major challenge encountered in using electrospun scaffolds for tissue engineering is 
the non-uniform cellular distribution in the scaffold with increasing depth under normal 
passive seeding conditions. Because of the small surface pores, typically few microns in 
diameter, cells tend to congregate and proliferate on the surface much faster compared to 
penetrating the scaffold interior. In order to overcome this problem, Chen et al used a 
vacuum seeding technique on PCL electrospun scaffolds while using NIH 3T3 fibroblasts as 
the model cell system. This serves as a precursor to the bilayer skin model where the 
fibroblasts would be residing at an intermediate layer and the keratinocytes would be on the 
top. Vacuum seeding was used in this study to enhance fibroblasts seeding and proliferation 
at different depths. Results showed that the kinetics of cell attachment and proliferation were 
a function of varying vacuum pressure as well as fibre diameter. Cell attachment reached a 
maximum between 2-8 in. Hg vacuum pressure and fell for lower vacuum pressures 
presumably because of cell loss through the filtration process. Cell proliferation and collagen 
secretion over five days indicated that vacuum pressure did not affect cellular function 
adversely. The combined impact of scaffold architecture (400 nm versus 1 µm average fibre 
diameter of scaffolds) and vacuum pressure were also compared. At a given pressure, more 
cells were retained in the 400 nm scaffolds compared to 1µm scaffolds. In addition, the cell 
intensity profile shows cell intensity peak shift from the top to the inner layers of the scaffold 
by lowering the vacuum pressure from 0 to 20 in. Hg. For a given vacuum pressure the cells 
were seeded deeper within the 1100 nm scaffold. The results indicated that cells can be 
seeded in PCL electrospun scaffolds at various depths in a controlled manner using a simple 
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vacuum seeding technique. The depth of seeding was a function of both pressure and scaffold 
fibre diameter [193]. 
 
Ananta et al developed a biodegradable hybrid scaffold consisting of a PLA-co-PCL 
(PLCL), and collagen, which was constructed by plastic compressing hyperhydrated collagen 
gels onto a flat warp-knitted PLCL mesh. Neonatal (foreskin) fibroblasts were seeded inside 
and on top of the collagen component. The collagen compaction process was characterized, 
and it was found that the duration, rather than the applied load under the test conditions in the 
plastic compression, was the determining factor of the collagen and cell density in the cell-
carrying component. Cells were spatially distributed in three different setups and statically 
cultured for a period of 7 days. Short-term biocompatibility of the hybrid construct was 
quantitatively assessed with AlamarBlue and qualitatively with fluorescence staining and 
confocal microscopy. No significant cell death was observed after the plastic compression of 
the interstitial equivalents, confirming previous reports of good cell viability retention. The 
interstitial, epithelial, and composite tissue equivalents showed no macroscopic signs of 
contraction and good cell proliferation was observed with a two- to threefold increase in cell 
number over 7 days. Quantitative analysis showed a homogenous cell distribution and good 
biocompatibility. The results indicate that viable and proliferating multilayered tissue 
equivalents can be engineered using the PLCL-collagen hybrid construct in the space of 
several hours. By suspending the cells homegenously in rapidly polymerising collagen gels, 
this allowed for the formation of a isotropic construct within the space of one hour as as 
opposed to weeks and has potential in in vitro tissue engineering of complex tissues such as 
skin, bladder, ureter and blood vessels [194]. 
 
8.8. Nerve engineering 
 During the 1990s Dendunnen and co-workers began evaluating PCL as a composite, 
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combined with PLLA in guided nerve regeneration [195]. Cytotoxicity tests, subcutaneous 
biodegradation and an in situ implantation studies in the sciatic nerve of the rat were 
undertaken. The nerve guide copolymer was found to be non-toxic, according to ISO/EN 
standards, and it showed a mild foreign body reaction and complete fibrous encapsulation 
after implantation. Onset of biodegradation of the inner layer was seen after one month of 
implantation. After 18 months of implantation complete fragmentation was observed, as well 
as a secondary inflammatory response characterized by foreign body giant cell activity and 
phagocytosis of polymer debris. Recovery of both motor and sensory nerve function was 
observed in all nerve guides. Further studies compared the speed and quality of nerve 
regeneration after reconstruction using the biodegradable nerve guide compared with an 
autologous nerve graft. A short nerve gap (1cm) was concluded to be better reconstructed 
using this composite compared with autologous nerve grafts, as evaluated using light 
microscopy, transmission electron microscopy and morphometric analysis [196, 197]. 
 
 Electrospinning provides constructs with high surface to volume ratios which is 
attractive to cell attachment. Fibres may also be aligned to provide directionality cues to 
cells; it’s no surprise that this technique has a large research focus in neuroscience. Kim et al 
looked at the role of aligned polymer fibre-based constructs in the bridging of long peripheral 
nerve gaps, demonstrating a significant role of sub-micron scale topographical cues in 
stimulating endogenous nerve repair mechanisms, depicted in Figure 15. Nisbet et al assessed 
axonal infiltration and guidance within neural tissue engineering scaffolds, made from PCL, 
and characterised of the inflammatory response. The extent of microglial and astrocytic 
response was measured following implantation of electrospun PCL scaffolds into the caudate 
putamen of the adult rat brain. No evidence of microglial encapsulation was found and 
neurites infiltrated the implants, evidence of scaffold-neural integration. Whilst the 
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inflammatory response was not influenced by the degree of PCL fibre alignment, the extent 
of neurite entry was. Large porosity, as was the case with the randomly orientated polymer 
fibres, enabled neurite infiltration and growth within the scaffold. However, neuronal 
processes could not penetrate scaffolds when fibres were partially aligned and instead, 
preferentially grew perpendicular to the direction of PCL fibre alignment at the implant-tissue 
interface i.e. perpendicular, not parallel, contact guidance was provided. This investigation 
highlighted that electrospun PCL fibres are compatible with brain tissue and provided 
preliminary insights regarding the influence of microglia and astrocytes in neural integration 
within such scaffolds [198]. 
 
PCL/collagen blends were investigated by Schnell et al as a conduit for axonal nerve 
regeneration after peripheral nerve injury. Aligned PCL and collagen/PCL nanofibres 
designed as guidance structures were produced by electrospinning and tested in cell culture 
assays. 100% PCL fibres were compared with 25:75% collagen/PCL blends. Both types of 
eletrospun fibres gave good Schwann cell migration, neurite orientation and process 
outgrowth, however Schwann cell migration, neurite orientation, and process formation of 
Schwann cells, fibroblasts and olfactory ensheathing cells were improved on collagen/PCL 
fibres compared to pure PCL fibres. While the velocity of neurite elongation from dorsal root 
ganglia explants was higher on PCL fibres, analysis of isolated sensory neurons showed 
significantly better axonal guidance by the collagen/PCL material. This study indicated that 
electrospun fibres comprising a collagen and PCL blend represents a suitable substrate for 
supporting cell proliferation, process outgrowth and migration and as such would be a good 
material for artificial nerve implants [199]. 
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The Neurolac® Nerve Guide comprising PDDLA-co-PCL (65/35) is indicated for 
reconstruction of a peripheral nerve discontinuity and provides guidance and protection to 
regenerated axons and prevents ingrowth of fibrous tissue into the nerve gap during nerve 
regeneration from the proximal to the distal nerve stump of the transected nerve. Neurolac® 
is designed to prevent kinking and collapse with associated patient comfort and early flexion 
of joints is feasible. Degradation of the Neurolac® Nerve Guide occurs through hydrolysis 
leading to gradual reduction of molecular weight, initial mechanical properties are reported to 
retain up to 10 weeks providing support and protection to the healing nerve, whereafter, rapid 
loss of mechanical strength and gradual mass loss occurs. The final degradation products, 
lactic acid and hydroxyhexanoic acid, are resorbed, metabolized and excreted by the body 
and studies show that the Neurolac® Nerve Guide has been resorbed within 16 months [200]. 
An interesting follow up study challenged the 16 month Neurolac® resorption claim. Meek et 
al studied the 2-year degradation and possible long-term foreign body reaction against the 
nerve guides after implantation in the sciatic nerve of the rat. After 2 years of implantation, 
the biomaterial could not be found macroscopically, however biomaterial fragments in 
company of multinucleated giant cells and macrophages were found along the regenerated 
nerve tissue. Although sufficient nerve regeneration was obtained after long-term 
implantation in the rat sciatic nerve, biomaterial fragments and foreign body reactions against 
these fragments, even after 24 months of implantation, could still be found. Nerve guides 
were shown to resorb, albeit not completely up to 2 years of implantation. It is still not known 
whether the remaining biomaterial fragments and foreign body reactions may cause 
granulomas or other complications after longer implantation periods [45]. 
 
9. Sterilisation of PCL-Based Drug Delivery Systems, Medical devices and Scaffolds 
 Sterilization of the final formulation containing the lactide and/or glycolide polymers 
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is an important issue often overlooked in the early stages of medical devices or drug delivery 
system development. Terminal sterilization and aseptic processing are two main methods 
reported for sterilization of PCL-based products. Steam sterilization usually involves 
subjecting the product to steam at 121°C for at least 20 min or 115°C for 30 min. This 
method cannot be used with PLGA systems because at higher temperature/pressure condition 
the polymer softens, melts and leads to deformation of the matrix form, and undergoes 
hydrolysis. Heat sterilization involves exposing the product to higher temperatures for longer 
periods of time which are destructive to both the polymer and the entrapped drug. 
 
 Sterilization using a gas such as ethylene oxide can be achieved when heat steam 
sterilization is harmful to the formulation. However, ethylene oxide is known to soften and 
plasticise these polymers. Also, the residual gas vapors left in these devices were found to be 
mutagenic, carcinogenic and allergic. Radiation sterilization (60Coy rays) has been used in 
several cases to sterilize formulations containing lactide and/or glycolide polymers [201]. The 
effect of radiation on PLGA has been a subject of various investigations [202]. Subjection of 
PCL to gamma irradiation produced dose-dependent polymer chain breakdown, molecular 
weight loss (decrease in inherent viscosity), increased in vitro and in vivo bioerosion rates 
and increased drug release kinetics. Aseptic processing is an effective but somewhat 
expensive technique for formulations containing PCL polymers. Because of the excellent 
solubility of the polymers in a number of organic solvents, they can be filter-sterilized. The 
drug delivery system can then be formulated in a clean room environment using Good 
Manufacturing Practice (GMP) protocols. PCL microparticles and other devices have already 
been introduced into the market and many more are undergoing clinical trials.  
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The effect of PCL-sterilisation by gamma irradiation (dose 2.5 Mrad) on: (1) 
degradation rate (catalysed by lipase), (2) mechanical properties, (3) the ability of cells to 
attach and subsequently grow on its surface was investigated by Cottam et al. Gel permeation 
chromatography (GPC) was used to determine the effects of gamma irradiation of weight 
average and number average molecular weights. Gamma irradiation significantly decreased 
the rate of degradation, although the rates depended on the initial mass of polymer; it also 
affected the appearance of the degraded specimens when they were examined by scanning 
electron microscopy. Irradiation also significantly increased the mechanical yield stress but 
not the failure stress of PCL. It caused a significant increase in molecular weight and 
decrease in molecular number which could be attributed to chain scission and cross-linking. 
Chondrocyte attachment and growth on PCL was not significantly affected by gamma 
irradiation [203]. 
 
10. Medical Grade Polycaprolactone: From Bench to Bedside  
Despite the plethora of excellent research utilizing PCL and its  composites for tissue 
engineering purposes, most studies still use PCL with impurities, from sources such as Sigma 
Aldrich, Solvay, and Union Carbide, often leading to cell culture and in vivo studies being 
unsuitable for translation into the clinical arena. Groups presently using non-clinically 
relevant PCL should consider switching to medical grade PCL (mPCL) (Birmingham 
polymers, Boehringer Ingelheim) after proof-of-principle studies have been undertaken; an 
approach which would enable a faster translation of technology from the laboratory through 
clinical trials and into the clinic. 
 
Over the last decade an intensive study into the biocompatibility, degradation 
behavior, mechanical properties and formability has resulted in the production of FDA-
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approved PCL implants, [48] [204, 205]. This work was initiated using Sigma Aldrich PCL 
for proof-of-principle studies before switching to mPCL and culminating in the production of 
first generation scaffolds using FDM. In vitro studies show clear cell attachment and 
spreading over the scaffold struts encircling and beginning to bridge across the pores as 
demonstrated by confocal laser scanning microscopy with clear cell sheet formation produced 
by cells generating their own extra cellular matrix as shown by SEM (Figure 7a,b).  
 
More recently, this work has matured to evaluate the parameters necessary to produce 
mPCL-tricalcium phosphate (mPCL-TCP) composites (so-called second generation 
scaffolds) by FDM techniques [112], with highly reproducible design and fabrication results 
for these 3D bioresorbable scaffolds, with the necessary properties for bone engineering 
[206] [207].  The inclusion of TCP increases hydrophilicity and osteoconductivity of the 
scaffold [208] [209]. 
 
A major concern with any work related to long-term resorbable polymers is the 
biocompatibility and mechanical behaviour of the implanted scaffold months down the line. 
In the present climate, insufficient long-term degradation studies have been undertaken 
looking at in vivo and in vitro degradation behavior of most resorbable polymers, particularly 
PCL [32]. Most groups look at the short term characteristics which are not necessarily 
extrapolated. Hutmacher and co-workers have systematically considered the long-term 
degradation kinetics of mPCL and mPCl-TCP in vitro, including an accelerated degradation 
system, utlising NaOH, and also long-term in vivo degradation studies studies [36] [46]. 
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The same mPCL-TCP scaffolds have been studied in vivo in several animal models 
and have been modified via the inclusion of fibrin glue and lyophilized collagen type I to 
incorporates biomolecules such as rhBMP2 [210] [47]. 
 
Most recently, long-term (2 year) in vivo implantation of mPCL-TCP scaffolds within 
a critical-sized pig cranial model has shown excellent bone regeneration, showing 
mineralisation throughout the constructs as demonstrated by histological staining and 
microcomputed tomography. It was notable that bone regeneration within mPCL-TCP 
scaffolds implanted alone and those implanted in combination with autologous bone marrow 
precursor cells was significantly different – with enhanced bone regeneration observed via 
the incorporation of cells. Figure 16a illustrates the implantation of an mPCL-TCP scaffold  
into a pig critical-sized cranial defect with near-complete mineralization observed within the 
scaffolds after 2 years as demonstrated using uCT scanning (Figure 16b). The corroborating 
histological analysis shows mineralized bone (black staining of calcium deposition using von 
kossa staining, Figure 16d) with histomorphometrical analysis giving an 86% mineralization 
value. 
 
11. Future directions - the use of PCL in the 21st Century  
A clear upward trend in PCL usage in research over the past decade signifies the 
recognition of this highly versatile resorbable polymer, particularly in the field of 
biomaterials and tissue engineering. The days of its utilization as a drug delivery device have 
been surpassed by the realization that PCL may be processed into composite structures with 
superior mechanical and biocompatible properties compared to the polymer on its own. Data 
analysed and discussed in this review allow us to conclude that PCL and its copolymers 
collectively provides a promising polymer platform for the production of longer-term 
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degradable implants which may be easily manipulated physically, chemically and 
biologically to possess tailorable degradation kinetics to suit a specific anatomical site.  
Despite a number of drug delivery and medical devices fabricated with PCL having 
FDA approval and CE Mark registration it is surprising that more devices and scaffold based 
on PCL have not been commercialized. One might speculate that many research groups may 
not have the infrastructure and capacity to perform translational research, but rather focus 
their studies and efforts on shorter-term, more achievable goals, including increasing 
publication counts. The difficulties in performing long-term degradation and biocompatibility 
studies are evident, particularly when one considers the typical length of grant funding 
awards would not last beyond 3 years but emphasis should not be lost on the importance of 
this longer term data, especially in view of the changes already observed in the 
biocompatibilities of some resorbable devices as degradation proceeds. The use of PCL and 
the excellent translational research which is already well underway holds great promise for 
future medical applications. This review highlights the huge diversity of these applications; 
ranging from sutures to wound dressings, artificial blood vessels, nerve regeneration, drug-
delivery devices and bone engineering applications. Finally, the return of PCL into the 
biomaterials and tissue engineering arena is a reflection of its tremendous promise as a 
scaffold candidate for tissue engineering, as we move forwards into the 21st century. 
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Figure Captions 
 
Figure 1 
Publications using PCL in the field of Biomaterials or Tissue Engineering during the last  
20years. Sourced from Web of Science. 
 
Figure 2 
Structures made from PCL: Nanospheres (a,b). Nanofibres (c,d). Foams (e,f). Knitted textiles 
(g,h,i). Selective laser sintered scaffold (j-o). Fused deposition modeled scaffolds (p-u).  
Copyright courtesy of Elsevier, Wiley and Mary Ann Liebert. 
 
Figure 3 
Degradation modes for degradable polymers: Surface erosion (a). Bulk degradation (b). Bulk  
degradation with autocatalysis (c).  
 
Figure 4 
Graphical illustration of the mass and molecular weight loss over time for a resorbable 
polymer such as PCL. Initial hydration (0-6 months), through degradation and mass loss (6 
12 months),  resorption (post 12 months) and metabolisation (post 18 months). 
 
Figure 5 
The degradation of PCL via hydrolysis intermediates 6-hydroxyl caproic acid and acetyl  
coenzyme A, which are then eliminated from the body via the citric acid cycle (a). Schematic 
visualization of how crystalline fragmentation could have taken place(b). Accelerated 
degradation of PCL over 5 weeks in NaOH (c). 
 
Figure 6 
Rat and Rabbit short and long-term biocompatibility studies. Implantation of 5mm PCL 
scaffold into calvaria (a). Schematic showing explanted reconstructed rabbit calvarial after 2-
year implantation. Center photo shows gross overview of reconstructed cranial defect site; 
from the top view, the remaining implanted PCL scaffolds are clearly visible along with bony 
mineralization observed within the scaffolds that has replaced the original struts. -CT three-
dimensional reconstructed images indicate dense mineralization within the defect space. 
Dotted rings indicate location of original defect created, and the images display only those 
thresholds that correspond with new bone (top inset). Histological sections were stained with 
Macneal's tetrachrome with von kossa, which reflects mineralization by staining calcium 
depositions black. The section gross overview of both defects demonstrates scaffold well 
integrated into the defects (bottom left inset). There is also bone in-growth and remodeling 
occurring within the scaffold and around its periphery, shown at higher magnification 
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(bottom right inset) (b). Bone specific staining of rhBMP-2 treated mPCL–TCP/collagen 
scaffolds demonstrate marked bone repair at 15 weeks.Traverse and longitudinal sections 
exhibited extensive bone healing within defects treated with rhBMP-2. Staining consists of 
MacNeal/von Kossa (black = bone, blue = ECM), Goldner's Trichrome (green = bone, 
red = osteoid), and Masson's Trichrome (dark blue = bone, red = cortical bone). Arrows 
indicate edge of host bone. Percentage of bone formation (% BV/TV) is measured by image 
analysis from transverse MacNeal/von Kossa sections and longitudinal Masson's Trichrome 
sections.Images taken with an objective of 40× indicate new bone (NB) contacting the 
implant strut (S) surface within rhBMP-2 treated defects whereas non-treated scaffolds 
stimulate a fibrous tissue interface and empty defects consist of fibrous tissue directly 
adjacent to host bone (HB). Significant values are represented as *P < 0.05 indicating 
significantly different to time-matched empty defect (c). 
Copyright courtesy of Wiley and Elsevier. 
 
 
Figure 7 
Scaffold-based tissue engineering aims to promote the repair and/or regeneration of tissues 
through the incorporation of cells and/or biomolecules within a 3D scaffold system which can 
be maintained in vitro culture conditions until implantation.  
 
Figure 8  
Graphical illustration of the complex interdependence of molecular weight loss and mass loss 
of a 3D scaffold plotted against the time frame for tissue engineering of a bone transplant. 
(A)Fabrication of a bioresorbable scaffold; (B) seeding of the osteoblast population into the 
scaffold in static culture (petri dish); (C) growth of premature tissue in a dynamic 
environment (spinner flask); (D) growth of mature tissue in a physiological environment 
(bioreactor); (E) surgical transplantation; (F) tissue engineered transplant 
assimilation/remodeling [111].Copyright courtesy of Elsevier. 
 
Figure 9 
Snapshot: Polymer scaffolds for tissue engineering. Fabrication routes for PCL scaffolds. 
 
 
Figure 10 
Schematic diagrams of: the process, direct polymer melt deposition. It has controllable 
parameters including control of the nozzle diameter, processing temperature, applied air 
pressure and movement velocity of the nozzle (a). The electrospinning process during which 
a drop of a polymer solution is ejected from the micro nozzle and spread onto a grounded 
substrate in the shape of a nanofibrous matrix (b). The developed hybrid process. Hybrid 
scaffolds containing microfibers and nanofiber matrices could be built via a combined 
process of continuous DPMD and electrospinning (c). Overall 3D woodpile structure with 
dimensions of 9 mm × 9 mm × 3.5 mm (d). The hybrid basic unit layer composed of 
microfibers and the electrospun nanofibers matrix (e).  Magnified images (f and g). 
Microfiber prepared for the pre-testing experiment: Microfibers with lengths of ca. 10 mm 
and diameters of ca. 0.4 mm (h). A schematic diagram of three different types of microfibers: 
microfiber-only, surface-modified microfibers with PCL nanofibers and the PCL/collagen 
blend nanofibers (i), SEM image of a microfiber coated with PCL/collagen nanofibers (j) and 
magnified image of the PCL/collagen nanofibers deposited on the surface of a microfiber (k). 
Copyright courtesy of Elsevier 
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Figure 11 
Schematic diagram showing the fabrication process of pore size gradient PCL scaffold by a 
centrifugation method and SEM photographs of the top surfaces of the selected PCL 
cylindrical scaffold sections along the longitudinal direction ( 100; *, average pore size). 
Copyright courtesy of Elsevier. 
 
 
Figure 12 
Pictures taken of the knitted valve inside the physiological flow simulator (a). Pictures taken 
of the porcine stent-less valve prosthesis inside the physiological flow simulator (b).  
Copyright courtesy of Mary Ann Liebert 
 
Figure 13 
Elastic behaviors of PLCL scaffolds. PLCL scaffolds (a) were extended at 250% of initial  
length (b) with 3MPa for 5 sec and recovered (c) by releasing the load. The scaffolds were  
twisted (d) and folded (e) via a cyclic strain apparatus. PLGA (f) was broken at 20% strain.  
Copyright courtesy of World Scientific. 
 
 
Figure 14 
SEM micrographs of the bilayered tubular construct: Bilayered tube (entire view) (a).  
bilayered tube wall(b). Details of the interface (mixing zone) between inner and outer  
layers (c–(). Details of the outer layer(PLA)(e–f). Details of the inner layer (PCL) (g–h). 
SEM micrographs of electrospun PLA/PCL constructs after culture with 3T3 mouse  
fibroblasts for: 1 week (i); 2 weeks (j); and 4 weeks (k). Copyright courtesy of Elsevier. 
 
 
Figure 15 
DRGs on aligned and random fibre film in vitro. (A–D) Double immunostained DRG  
on the aligned fibre film: (A) representative montage of NF160 (a marker for axons)  
immunostained DRG neurons on the film and (B) montage of S-100 (a marker for Schwann  
cells) immunostained Schwann cells on the film. (C) Magnified NF160 (red, from box in A)  
and S-100 (green, from box in B) overlapped image. (D) Double immunostained aligned  
axons (NF160, red) and endogenously deposited laminin protein (laminin, green). (E–I)  
Fabrication of the fibre films and distribution of alignment of the films. (E) Schematic of  
aligned fibre film fabrication by electrospinning process. Random fibre film was deposited 
on a flat metal target instead of on a high-speed rotating metal drum. (F) and (H)   
Representative SEM image of the aligned fibres (F, magnified fibres below) and the random 
fibres  
(H). Scale bar ¼ 1 mm and 30 mm, respectively. (G) and (I) Distribution of fibre alignment  
in aligned (G) and random fibre (I). (J) and (K) Double immunostained DRG on the random 
fibre film: (J) representative montage of NF160þ neurons and (K) S-100þ Schwann cells.  
Scale bar ¼ 500 mm. (L) Shows the quantitative comparison of orientation of neurite  
outgrowth on the aligned and random fibre film. Direction of arrows indicates the orientation 
 of neurite outgrowth, and length of arrows indicates the rate of occurrence (percentage) 
(n ¼ 25 per DRG). (M) Shows the quantitative comparison of the extent of neurite outgrowth  
 and Schwann cells migration on the films. The distance between the longest neurite  
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outgrowth (n ¼ 25 per DRG)/the furthest migrated Schwann cells (n ¼ 10 per DRG) and  
DRG was measured and averaged. *P < 0.05. Error bar ¼ s.e.m. 
Copyright courtesy of Elsevier 
 
Figure 16 
Implantation of the mPCL-TCP scaffold into the pig cranium (a). SEM analysis using 
backscattered electron mode. Visualisation of the calcium content represented in grey (b). 
Histological analysis showing new bone formation (nb) scaffold struts (s) osteoblasts (ob) 
and osteocytes (oc). Extensive mineralization is evident throughout the scaffold (c). 
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Table 1 – Polymer properties 
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Table 2  
Definitions of biodegradable, bioresorbable, bioabsorbable and bioerodable, according to 
Vert (1992). 
 
 
Biodegradables are solid polymeric materials and devices which break down due to 
macromolecular degradation with dispersion in vivo but no proof for the elimination from the 
body (this definition excludes environmental, fungi or bacterial degradation). Biodegradable 
polymeric systems or devices can be attacked by biological elements so that the integrity of 
the system, and in some cases but not necessarily, of the macromolecules themselves, is 
affected and gives fragments or other degradation by-products. Such fragments can move 
away from their site of action but not necessarily from the body. 
Bioresorbables are solid polymeric materials and devices which show bulk degradation and 
further resorb in vivo; i.e. polymers which are eliminated through natural pathways either 
because of simple filtration of degradation by-products or after their metabolization. 
Bioresorption is thus a concept which reflects total elimination of the initial foreign material 
and of bulk degradation by-products (low molecular weight 
compounds) with no residual side effects. The use of the word ‘bioresorbable ' assumes that 
elimination is shown conclusively. 
Bioerodibles are solid polymeric materials or devices, which show surface degradation and 
further, resorb in vivo. Bioerosion is thus a concept, too, which reflects total elimination of 
the initial foreign material and of surface degradation by-products (low molecular weight 
compounds) with no residual side effects. 
Bioabsorbables are solid polymeric materials or devices, which can dissolve in body fluids 
without any polymer chain cleavage or molecular mass decrease. For example, it is the case 
of slow dissolution of water-soluble implants in body fluids. A bioabsorbable polymer can be 
bioresorbable if the dispersed macromolecules are excreted. 
 
